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Arbete och Hälsa
Arbete och Hälsa (Work and Health) is a
scientific report series published by the
National Institute for Working Life. The
series presents research by the Institute’s
own researchers as well as by others, both
within and outside of Sweden.  The series
publishes scientific original works, disser-
tations, criteria documents and literature
surveys.
Arbete och Hälsa has a broad target-
group and welcomes articles in different
areas. The language is most often English,
but also Swedish manuscripts are
welcome.
Summaries in Swedish and English as well
as the complete original text are available
at www.niwl.se/ as from 1997.
Preface
The Criteria Group of the Swedish National Institute for Working Life (NIWL) has the
task of gathering and evaluating data which can be used as a scientific basis for the
proposal of occupational exposure limits given by the Swedish Work Environment
Authority (SWEA). In most cases a scientific basis is written on request from the SWEA.
The Criteria Group shall not propose a numerical occupational exposure limit value but,
as far as possible, give a dose-response/dose-effect relationship and the critical effect of
occupational exposure.
In searching of the literature several data bases are used, such as RTECS, Toxline,
Medline, Cancerlit, Nioshtic and Riskline. Also information in existing criteria documents
is used, e.g. documents from WHO, EU, US NIOSH, the Dutch Expert Committee for
Occupational Standards (DECOS) and the Nordic Expert Group. In some cases criteria
documents are produced within the Criteria Group, often in collaboration with DECOS or
US NIOSH.
Evaluations are made of all relevant published original papers found in the searches. In
some cases information from handbooks and reports from e.g. US NIOSH and US EPA
is used. A draft consensus report is written by the secretariat or by a scientist appointed
by the secretariat. The author of the draft is indicated under Contents. A qualified
evaluation is made of the information in the references. In some cases the information can
be omitted if some criteria are not fulfilled. In some cases such information is included in
the report but with a comment why the data are not included in the evaluation. After
discussion in the Criteria Group the drafts are approved and accepted as a consensus
report from the group. They are sent to the SWEA.
This is the 22nd volume which is published and it contains consensus reports approved
by the Criteria Group during the period July 2000 to June 2001. These and previously
published consensus reports are listed in the Appendix (p 90). Technical editing for
printing was made by Karin Sundström.
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1Consensus Report for Ethylenethiourea
September 27, 2000
This Consensus Report is based largely on a criteria document from the Dutch
Expert Committee for Occupational Standards (DECOS) (15), and takes into
account research published through 1999. The last literature search was made in
May, 2000.
Chemical and physical data
CAS No.: 96-45-7
Synonyms: ETU
imidazoline-2-thiol
2-imidazolidinethione
2-mercaptoimidazoline
Formula: C3H6N2S
Structure:
Molecular weight: 102.15
Melting point: 203-204 °C
Relative density: 1.4 (water = 1)
Vapor pressure: 0.0027 hPa (100 °C) (3)
Solubility: in water: 20 g/liter (30 °C)
in ethanol: moderate
in acetone, ether, chloroform: insoluble
Ethylenethiourea (ETU) at room temperature is a white to pale green, crystalline
powder with a weak amine-like odor and bitter taste. ETU is resistant to hydro-
lysis, but is readily oxidized in biological systems and on exposure to air and light.
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2Occurrence, use
Occupational exposure to ETU may occur in the rubber industry, where it is used
for vulcanization of polyacrylate rubber and as an accelerator in the manufacture
of neoprene rubber. ETU has also been used in production of antioxidants and
synthetic resins. Exposure to ETU may also occur in forestry and agriculture,
where metallic salts of ethylenebisdithiocarbamate (e.g. maneb, mancozeb, zineb)
are used as fungicides. These products usually contain ETU as an impurity. ETU
is formed in biological systems by the breakdown of ethylenebisdithiocarbamate.
ETU can be synthesized by a reaction between ethylene diamine and carbon
disulfide, followed by addition of hydrochloric acid to close the ring.
ETU does not occur naturally in the environment. Non-occupational exposure
in Poland was estimated by measuring the concentration of ETU in various foods,
and intake was found to be between 0.01 and 1 µg/kg body weight/day (33). In the
populations of four Italian towns, measured excretion of ETU in urine was in the
range <0.1 to 8.3 µg/g creatinine (5). In a wine district where ethylenebisdi-
thiocarbamate was used as a fungicide, excretion of ETU in urine was higher:
up to 61.4 µg/g creatinine. The highest values were found in smokers and wine
drinkers (5). In a laboratory study with five volunteers in which the amount of
ETU in diet was determined by analysis, it was found that most of the ETU in
urine originated from intake of wine (4). ETU has been found in tobacco smoke (8
to 27 ng/cigarette in 4 of 12 tested brands) (7). FAO/WHO have proposed 4 µg/kg
body weight/day as an acceptable intake of ETU (19). The EU threshold limit
value for ETU in foods is 50 µg/kg (cited in Reference 17).
In a Finnish study of groups of agricultural and forestry workers who used
mancozeb or maneb fungicides (containing ethylenebisdithiocarbamate), air
concentrations of ETU around spraying ranged from 0.14 to 0.6 µg/m3 (average
values within the groups). Air levels were higher around weighing (highest average
value 1.81 µg/m3). The highest concentration of ETU measured in urine was
23 µg/liter (49). Another Finnish study of 29 potato farmers (probably including at
least some of the participants in the previously mentioned study) showed air
concentrations of 0.004 to 3.3 µg/m3 in the breathing zone and 0.006 to 0.8 µg/m3
in the tractor cab. In the 24 hours immediately after the exposure, excretion of ETU
in urine was in the range 0.09–2.5 µg/mmol creatinine (0.8-22.1 µg/g creatinine)
(52). In 1980, air concentrations of 120 to 160 µg/m3 were measured in an English
rubber factory where ETU was used in a process that generated dust (84). In an
ETU production plant in England, air levels shown on personal monitors were 10
to 240 µg/m3, with a single reading of 330 µg/m3 (84).
Uptake, distribution, excretion
Data from animal experiments show that ETU is rapidly absorbed from the
digestive tract. IPCS/WHO report that ETU was identified in the blood of rats as
early as 5 minutes after oral administration of 14C-ETU (100 mg/kg body weight)
3(33). A study with guinea pigs (reviewed in Reference 3) showed that uptake of
ETU through intact skin was relatively slow: 14% of 2-14C-ETU (15 mg/ml, 1 ml
applied to an area of 4 x 4 cm) was absorbed within 24 hours. If the skin was
damaged, uptake within 24 hours was 42%. The only laboratory data indicating
respiratory uptake of ETU are in unpublished studies on rats (3). There are no
quantitative data on ETU uptake by humans, although the substance has been
found in urine of occupationally exposed persons (49, 52). It was found that ETU
in the urine of workers producing fungicides was correlated to the amounts of
mancozeb and ETU on their hands (6). It was concluded that most of the ETU
exposure in this work environment was due to skin uptake (6).
Regardless of the path of absorption, ETU accumulates in the thyroid (15).
Single doses of ETU (20 mg/kg body weight) were given to rats and guinea pigs
by gavage, and 96 hours later there was a much higher accumulation of ETU in
thyroid than in liver, kidney, heart and muscle tissue, where concentrations were
about the same (64). When 2-14C-ETU was given to pregnant rats, the radio-
activity was evenly distributed in all examined tissues except the thyroid, where
accumulation was particularly marked after 24 hours (>30 times). After 2 and 6
hours, the concentration in the thyroid was two to three times higher than in other
tissues. The concentration of ETU was somewhat lower in fetal tissue than in the
mothers. This study also shows that ETU can cross the placental barrier (38).
Rhesus monkeys (2 females) were given single oral doses of ETU (40 mg/kg body
weight) and no accumulation in thyroid was noted 48 hours later (1).
Groups of 6 rats of each sex were given 0, 2, 20, 200, 1000 or 2000 µg 14C-
ETU/day for 7 days. Doses were equivalent to 0, 0.1, 1, 10, 50 or 100 ppm in feed.
The amount of 14C in thyroid increased with increasing dose, but only up to 50
ppm. No further increase was noted at 100 ppm. Seventeen days after the last dose
of ETU, the 14C level in thyroids had declined by 80 to 94%. This shows that ETU
and/or its metabolites do not accumulate permanently in the thyroid (57).
Most ETU is eliminated in urine. In an experiment in which two female rhesus
monkeys were exposed to 14C-ETU (40 mg/kg body weight, gavage) 47% and
64% of the radioactivity was recovered in urine within 48 hours. Feces contained
less than 1.5% (1). In a similar experiment with rats and guinea pigs (20 mg/kg
body weight) 65% (rats) and 47% (guinea pigs) of radioactivity was recovered in
urine within 48 hours (61% and 45% within 24 hours) (64). In a 28-day study with
rats it was found that the relative amounts of ETU in urine increased with in-
creasing dose, possibly indicating that metabolism of ETU became saturated.
At daily doses of 10.6, 17.6 and 23.4 mg/kg body weight, excretion in urine was
on average 25%, 36% and 49% of the dose respectively (50).
For ETU and its metabolites, IPCS/WHO report a half time of 28 hours in
monkeys (9.3 mg 2-14C-ETU, per os), 9-10 hours in rats (240 mg/kg body weight,
per os) and 5 hours in mice (240 mg/kg body weight, per os) (33, 71). The half
time for 14C-ETU (4 mg/kg body weight, i.v.) in the blood of 2 female cats was
3.5 hours (34). In humans, the half time for elimination of ETU via kidneys is
4estimated to be between 32 and 100 hours (49, 52). It is possible that the long half
time is due to slow uptake through the skin (52).
Biotransformation
Rats and cats were given oral doses of 14C-ETU (4 mg/kg b.w.); 24-hour urine
samples from the rats contained mostly unchanged ETU, ethyleneurea, 4-
imidazoline-2-one and imidazoline, and those from the cats contained mostly S-
methyl ETU, unchanged ETU and ethyleneurea (34). Biotransformation was more
extensive in the cats than in the rats (34). Very small amounts of 1-methyl thio-
urea were found in plasma of rats after oral administration of ETU (48). It was
shown in a study with mice that biotransformation of ETU involves oxidation of
the sulfur atom, with 2-imidazoline-2-yl-sulfenate as the primary product (78).
There are no data on metabolic pathways in humans.
In mice, ETU is metabolized primarily by the microsomal flavin-containing
monooxygenase system (FMO) (30). The FMO-dependent binding of ETU
metabolites to proteins in the liver may contribute to the chronic liver toxicity that
has been observed in mice (15, 30). Mice metabolize ETU more rapidly than rats
do, which may explain why ETU shows acute toxicity but not teratogenicity in
mice (see below). Oral administration of ETU (50 to 1000 mg/kg body weight)
induced cytochrome P-450 (aniline hydroxylase: CYP2E1) activity in mice (61),
but reduced the activity in rats (54, 61).
Nitrosation
N-nitroso-ethylenethiourea, a nitrosamide containing sulfur, may be formed from
ETU in the presence of nitrite in acid environments. Nitrosamides spontaneously
break down to carbonium ions at physiological pH, and are mutagenic without
metabolic activation (47).
Sodium nitrite, which is used to preserve meat, is the primary dietary source of
nitrites. In Europe, the daily intake of sodium nitrite is about 4 mg per person.
Nitrates may also play some role, since they can be reduced to nitrites in the
mouth. Intake of nitrate is mostly from vegetables, and on average amounts to
about 100 mg per person per day. It can be assumed that about 6% of this (6 mg)
is transformed to nitrite, increasing the daily nitrite intake to about 10 mg per
person (81). The formation of N-nitroso-ETU is probably much less likely with
inhalation or skin uptake of ETU than with oral exposure.
Biological monitoring
As mentioned previously, urine samples can be used for biological monitoring that
reflects the past 24 hours of exposure to ETU. Analysis of ETU bound to hemo-
globin has been proposed as a method for estimating longer exposures (up to 4
months). Of 15 workers occupationally exposed to mancozeb, 40% had
identifiable Hb adducts of ETU (0.5-1.42 pmol/mg Hb) (69). It has been
demonstrated in studies with rats that ETU, after metabolic activation –
5presumably to a reactive sulfenic acid (see under Biotransformation) – forms
covalent bonds to cysteine in hemoglobin in the form of a mixed disulfide. Since
glutathione has the same ability to bind the reactive metabolite of ETU, only a
very small proportion is bound to Hb. It appears that, at comparable exposures,
more Hb adducts are formed in humans than in rats (69).
Toxic effects
Human data
In an English study from 1984, thyroid function was examined in eight production
workers from a plant that produced ETU and five workers (mixers) from a factory
where ETU was used in rubber production (84). Air concentrations of ETU ranged
from 10 to 330 µg/m3 in the production plant and from 120 to 160 µg/m3 in the
rubber factory. Thyroid function was measured as levels of T4 (thyroxine), TSH
(thyroid-stimulating hormone) and TBG (thyroxine-binding globulin) in serum. It
was found that T4 levels were lower in the mixers (geometric mean 80.5 nmol/l)
than in the process workers (geometric mean 96.4 nmol/l) and an unexposed
control group (geometric mean 105.7 nmol/l), but the individual values were
within the range of normal reference values for T4 (50 to 150 nmol/l) (53). TSH
and TBG levels were normal in all the subjects except one mixer, who had an
elevated TSH level (84).
The question of whether ETU is teratogenic was addressed in a study of 699
women of childbearing age who had come into contact with ETU at a rubber
factory in Birmingham, England. Of these, 255 women were traced who had
borne a total of 420 children. Only 59 of the women had worked at the factory
during early pregnancy, and none of these had borne children with birth defects.
In the entire group of 420 children there were 11 with birth defects; no more than
predicted. Three of these children had been born before their mothers began work
at the factory, and the other eight had been born at least a year after their mothers
had quit working there (83).
There is a study on the incidence of thyroid cancer among 1,929 workers who
had worked in several rubber factories and in a factory for production of ETU in
England. No cases of thyroid cancer in this group had been reported to the
regional cancer register between 1957 and 1971. The expected incidence of
thyroid cancer was 2.6 per 100,000 (0.6 for men and 2.0 for women), which
would be less than one case (0.05) in a group of this size (83).
An ecological study, not reviewed by referees (von Meyer WC, Philadelphia,
PA: Rohm & Haas Company, 1977) is cited by Houeto et al. (29). In this study
there was a trend (not statistically significant) to elevated incidences of liver and
thyroid cancer in several parts of the United States where use of dithiocarbamate
pesticides had increased.
A study of 49 Mexican workers who sprayed tomatoes with ethylenebisdithio-
carbamate fungicides without using protective clothing or masks revealed elevated
TSH levels (2.13 ± 0.15 mIU/liter; 1.61 ± 0.l9 mIU/liter in 24 unexposed
6controls). Levels of T4 were unaffected, however, and no symptoms of changes in
thyroid function were observed, although no clinical examination was made.
Exposure to ETU was estimated by measuring the concentration of ETU in
morning urine the day after taking the blood samples used for the other analyses.
The average level among the exposed subjects was 58 ± 26 ppb. All the controls
and 34% of the exposed subjects had urine levels below the detection limit of 10
ppb. A cytogenetic examination revealed that the exposed workers had
significantly elevated levels of sister chromatid exchanges and chromosome
aberrations in the form of total translocations, but it is impossible to determine
whether this damage was due to ETU or to other substances in the fungicides (85).
Elevated frequencies of chromosome aberrations and sister chromatid exchanges
are also reported in an earlier study of 44 workers exposed to mancozeb (36).
Patch tests with ETU (2% in vaseline) were given to 200 patients at a Polish
dermatology clinic: there was one positive response (0.5%) (74). There is a
reported case of allergic contact dermatitis in a 53-year-old woman who had
worked in production of rubber goods for 13 years. She had a positive reaction to
a patch test with ETU (1-0.01% in water). Results for 20 controls were negative
(9). A positive reaction to ETU has also been reported in a dentist with contact
eczema on the fingertips (37).
Among 11 cases of contact allergy after use of a rubber heat retainer, 6 of 7
tested patients had positive reactions to patch tests with ETU (1%), and all 7 of
them had positive reactions to diphenylthiourea. This chemical could be identified
in the heat retainers, and was probably the cause of the contact allergy. The role of
ETU is less clear, since this substance could not be identified in the heat retainers
(60).
Animal data: Short-term effects (up to 4 month
The acute toxicity of ETU is low. The reported LD50 for ETU given orally to rats
is between 545 and 1830 mg/kg body weight. For oral doses to mice and hamsters,
the LD50 is more than 3000 mg/kg body weight (58). Cats seem to be more
sensitive (45). A lethal dose for skin exposure of pregnant rats (ETU dissolved in
DMSO) has been reported to be about 2250 mg/kg body weight (86).
Skin
Ethylenethiourea apparently causes little skin irritation. The threshold value for an
effect of ETU on the skin of guinea pigs was >10% in water (59). ETU was tested
for allergenic potential in the guinea pig maximization test, and ranked as weak
(59).
Thyroid
Repeated exposure to ETU inhibits thyroid function in laboratory animals (15).
Rats (Wistar males) were given ETU in drinking water (0 to 300 mg/l, ad libitum)
for 28 days. The treatment resulted in a dose-dependent (11-23 mg/kg body
weight/day) inhibition in secretion of T3 and T4 and a tenfold increase of TSH. No
7changes in thyroid were detected under an optical microscope, but electron
microscopy showed some changes in thyroid follicular cells (51).
In a 13-week study, F344/N rats (10 of each sex per group) were given feed
containing 60, 125, 250, 500 or 750 ppm ETU (66). Histopathological changes
were seen in thyroid and pituitary of both males and females. Diffuse hyperplasia
in thyroid follicular cells was observed in both sexes at all dose levels. The
NOAEL was therefore reported to be below 60 ppm in feed (≈ 3.0 mg/kg body
weight/day for males and 4.3 mg/kg body weight/day for females) (66).
In a 90-day study, Sprague-Dawley rats (both sexes, 12 per group) were
exposed to 75 or 100 ppm ETU in feed. At 100 ppm the serum level of T4 was
reduced and the T3/T4 quotient and TSH levels were elevated in the males, while
there was a smaller effect on the females. At 75 ppm the T4 levels were reduced in
both sexes, but since neither T3, TSH nor thyroid weights were affected, the
animals were regarded as having normal thyroid function (67).
In another 90-day study with rats, it was found that 125 mg ETU/kg feed
(125 ppm) reduced levels of T3 and T4 and markedly raised levels of TSH, and
also enlarged thyroids, whereas 25 ppm yielded lower levels of T4 and thyroid
hyperplasia on day 60 – which, however, was not seen on either day 30 or day 90.
The authors gave a NOAEL of 25 ppm (≈ 1.8-2.2 mg/kg body weight/day) for 90
days of exposure to ETU in feed (22). The Dutch criteria group made a different
assessment, and gave a NOAEL of 5 ppm (≈ 0.4 mg ETU/kg body weight/day)
(15).
Groups of 10 Osborne-Mendel rats (males) were given feed containing 0, 50,
100, 500 or 750 ppm ETU for up to 120 days (25). Relative thyroid weights were
elevated at all examination times (30, 60, 90 and 120 days) in the animals re-
ceiving at least 100 ppm ETU in feed, but only at the last examination in the rats
receiving 50 ppm. Thyroid weights were slightly but significantly elevated at the
two lowest doses (at most 133% of controls), but thyroid weights in animals
exposed to 500 or 750 ppm were about 5 times those of controls. An effect on
thyroid function, measured as reduced uptake of 131I, was observed only in the two
highest dose groups after 4 hours, and also in the 100-ppm dose group after 24
hours. No histological changes were observed in the thyroids of rats given 50 ppm
ETU in feed (25). In the assessments of the IARC (31) and DECOS (15), 50 ppm
ETU in feed (according to DECOS, about 3.7 mg/kg body weight/day) should be
regarded as the NOAEL in this study.
Young Wistar rats (males, 80-90 g) were exposed to ETU in feed for 5 days. A
slight but significant elevation of TSH and reduction in levels of free T4 were
observed at 5 ppb, but not 500 ppb (63). The authors suggest that the reversed
dose-response relationship might be due to tolerance development or more rapid
detoxification.
An unpublished report (reviewed in Reference 3) describes an inhalation study
(nose-only exposure) with Wistar rats, in which groups of 5 males and 5 females
were exposed to 0, 10, 40, or 200 mg/m3 ETU 6 hours/day, 5 days/week for 4
weeks. The particle size suggests that the ETU penetrated deep into the lungs. The
8animals in the two highest dose groups had lower body weights and lower feed
intake. The number of reticulocytes in the highest dose group (200 mg/m3) was
half that of controls. Effects on thyroid – lower T4, histological changes – were
dose-dependent, and observed at 40 mg/m3 and above. Hyperplasias in the anterior
pituitary and in mandibular glands were also observed. The NOEL was reported to
be between 10 and 40 mg/m3.
A series of biochemical experiments made to elucidate the mechanism behind
ETU’s effect on thyroid showed that ETU inhibits thyroid peroxidase. The
inhibition occurred only in the presence of iodide, and involved simultaneous
oxidation of ETU to imidazoline and bisulfite. Inhibition of thyroid peroxidase
ceased when all the ETU had been oxidized. ETU did not form covalent bonds to
thyroid peroxidase. Since the inhibition was reversible, occasional exposure to
small amounts of ETU should not have much effect on thyroid function (16).
In summary, several short-term studies of thyroid effects have shown that the
NOAEL for rats is in the range 0.4 to 4 mg/kg body weight/day. For mice, which
are less sensitive than rats, the NOAEL for thyroid effects is 50 mg/kg body
weight/day (15).
Liver
Effects on liver (increased liver weight, triglycerides in liver, fatty degeneration)
were observed in rats 24 hours after doses of 920 mg ETU/kg body weight
(gavage) (90). DECOS (15) reports a study of male rats that received ETU in
drinking water for up to 8 months. Liver morphology was not affected by 50 mg/l
(15 mg/kg body weight/day) whereas 500 mg/l had effects which included
increasing the amount of smooth endoplasmic reticulum.
Nervous system
Effects on the peripheral nervous system were observed in rats given 600 ppm
ETU in feed for 4 weeks (90). Toxic effects on the central nervous system were
observed in 4 of 7 pregnant cats given 10 mg ETU/kg body weight/day for 20
days (45). The results of a study in which ETU was given to rats in drinking water
(0 to 300 mg/l) led the authors to state that the target organ for ETU’s neurotoxic
effect was cholinergic peripheral nerves rather than the CNS (77).
Kidneys
In a 28-day study, rats were given drinking water containing 0, 100, 200 or
300 mg/l ETU (≈ 0, 11, 18, or 23 mg ETU/kg body weight/day) and effects on
kidneys were examined (50). Weight gain in the two highest dose groups was
lower than in controls, possibly because of slight dehydration, since these animals
drank less than normal. No significant changes in urine composition were found
(Na, K, protein, glucose, uric acid, specific gravity, vasopressin). Examination
under optical microscope revealed no histological changes in the kidneys, but
electron microscopy revealed changes in the proximal tubuli of animals exposed
to 300 mg/l. In another study with rats, in which ETU was given by gavage in
single doses of 50 to 500 mg/kg body weight, dose-dependent indications of
9kidney damage (including proteinuria) were observed at doses of 100 mg/kg or
higher (55).
Animal data: long-term effects
Mice and rats
The NTP made a long-term exposure study in which B6C3F1 mice and F-344/N
rats were given ETU in feed (66). The study combined perinatal exposure with a
conventional NTP protocol for studies of chronic toxicity. Long-term exposure of
the mice caused non-neoplastic damage to thyroid, liver and pituitary (11, 66)
Vacuolization of cytoplasm in thyroid follicular cells was observed in both male
and female mice exposed to 330 ppm ETU (≈ 66 mg/kg b.w./day) for 2 years
(LOAEL). Levels of T4 were significantly lower in both sexes, and TSH levels
were slightly elevated (11).
The ETU-exposed rats showed thyroid damage but no non-neoplastic damage to
liver or pituitary (11, 66). Thyroid hyperplasia was observed in both male and
female rats exposed to 83 ppm for 9 months, and was accompanied by significant
reductions of T3 and T4 and elevated TSH. A lower concentration (25 ppm) also
had effects on T3 , T4 and TSH in the animals that had been exposed perinatally to
9 ppm. At the close of the two-year study no histopathological effects were
observed in the rats exposed to levels below 83 ppm, but 60 to 90% of those
exposed to 83 ppm and 250 ppm had hyperplasias in thyroid follicular cells (11).
In a French study, groups of 20 male and 20 female rats were exposed to 0, 5, 17,
60 or 200 ppm ETU in feed for two years (23). Reduced food intake and effects
on body weight were reported at 17 ppm and higher. Significantly elevated serum
cholesterol levels were found in all dose groups and both sexes. The elevations
were constant over time (3 to 24 months) and dose-dependent: 5 ppm ETU raised
the cholesterol level by about 30%, and 200 ppm by about 80%. Slightly elevated
serum levels of the hepatic enzymes alkaline phosphatase (ALP) and alanine
aminotransferase (ALT) were also observed, but they were temporary and not
clearly related to the dose of ETU. The intake of ETU at 5 ppm in feed was
calculated to be about 0.37 mg/kg b.w./day at one month of age, and 0.22 to 0.26
mg/kg b.w./day at 3 months and older.
Hamsters
In conjunction with the study described above, 20 hamsters of each sex per group
were exposed to ETU in feed for 20 months. Dose levels were 0, 5, 17, 60 or
200 ppm (23). Reduced food intake and lower body weights were observed at
60 ppm and higher. As with the rats, cholesterol levels in serum in both sexes and
at all dose levels and all times were significantly above those of controls. At the
end of the 20-month exposure, ALP and ALT levels were also significantly
elevated (about 40% at most) in both sexes at all dose levels. Glucose-6-phosphate
dehydrogenase in the liver was significantly lower (as much as 60%) in both sexes
at all dose levels.
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Dogs
Beagles of both sexes have also been experimentally exposed to ETU. Exposures
have been for 4, 13, or 52 weeks. These studies have not been published, but have
been assessed by the FAO/WHO expert panel (20). In the 4-week study, the dogs
(2 of each sex per group) were exposed to concentrations of 0, 200, 980 and
4900 ppm in feed. Reduced weight gain, lower T4 and T3 levels and thyroid
enlargement were observed at 980 ppm. In the 13-week study, the dogs (4 of each
sex per group) were exposed to 0, 10, 150 and 2000 ppm in feed. No effects were
noted at 10 ppm (NOAEL), which according to the WHO expert group is equi-
valent to 0.39 mg/kg b.w./day. At 150 and 2000 ppm there were statistically
significant reductions of hemoglobin, hematocrit and red blood cells, and a
statistically significant elevation of cholesterol level. Effects on the thyroid were
seen only at 2000 ppm. In the 52-week study, the dogs (4 of each sex per group)
were exposed to 0, 5, 50 or 500 ppm ETU in feed. No effects were observed at
5 ppm (NOAEL). The 50 ppm exposure resulted in reduced weight gain, thyroid
hypertrophy with colloid accumulation, slight increase in thyroid weight and an
accumulation of pigment in the liver (20).
Monkeys
Rhesus monkeys caught in the wild (5 of each sex per group) were exposed to
ETU in diet for about 6 months in two studies which have not been published but
are mentioned by the FAO/WHO expert panel (20). The studies report increased
uptake of 125I at a concentration of 50 ppm, and elevated thyroid and spleen
weights in males at 150 ppm and above and in females at 50 ppm and above.
These studies were judged to be unreliable, however, since the monkeys were
not entirely healthy (20).
Genotoxicity, mutagenicity
The results of various short-term tests published prior to 1993 have been
summarized and evaluated by Dearfield (14). The overall impression from the
large number of bacterial tests made with ETU is that the substance has weak but
dose-dependent mutagenic activity which is not apparent at concentrations below
1000 µg per plate (20 ml medium), and that the mutations are base-substitutions.
High concentrations have caused aneuploidy (incomplete chromosome separation)
in yeast cells, mutations in Tradescantia plants, and gene mutations and chromo-
some aberrations in mammalian cells. In vivo tests with mammals have usually
been negative (14).
Subsequently published studies report aneuploidy in yeast at a concentration
of about 500 µg/l, and inhibited mitosis and elevated numbers of chromosome
aberrations in onions at concentrations of 2.5 and 25 µg/ml (21). Increased
numbers of somatic mutations were observed in two insecticide-resistant strains
of Drosophila when the larvae were raised on food containing 50 or 100 mg
ETU/liter (70). The Comet assay was used to identify and quantify the DNA
damage (alkaline labile sites) in mice that had been treated with ETU (76). ETU
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was tested along with 7 other substances that cause hepatic cancers in experi-
mental animals but have not been shown to cause micronuclei in the bone marrow
cells of mice. The mice were killed 3 hours and 24 hours after receiving a single
intraperitoneal dose of 2000 mg/kg body weight. The ETU caused DNA damage
in cells from liver, lung, spleen, kidney and bone marrow.
Mutagenicity in bacteria is greatly increased if ETU is combined with nitrite,
and N-nitroso ETU is strongly mutagenic in bacterial tests (79, 80, 82). A re-
markable sensitivity to ETU plus sodium nitrite was observed in two studies using
the host-mediated assay method (8, 82). In mice given an oral dose of 50 mg
NaNO2/kg body weight, there was a significant, dose-dependent increase in the
number of mutations in Salmonella typhimurium G46 when the mice were
simultaneously given ETU in doses of 1 to 25 mg/kg body weight (82).
The interaction between ETU and sodium nitrite has also been studied with
regard to induction of dominant-lethal mutations in mice (88). Daily doses of ETU
(150 mg/kg b.w.) and NaNO2 (50 mg/kg b.w.) were given orally for five conse-
cutive days to male mice, which were mated with groups of untreated females for
the following six weeks. The females mated six weeks after the treatment had a
greatly reduced proportion of pregnancies as well as lower numbers of implants
and living embryos. The delayed effects were regarded as an indication that ETU
in the presence of NaNO2 forms N-nitroso ETU and damages the stem cells
(spermatogonia). An increase in the number of genetic aberrations was also seen
in stem cells of mice after treatment with 100 mg N-nitroso ETU/kg b.w. Neither
ETU nor N-nitroso ETU has been tested on mammals with methods that can
reveal hereditary (non-lethal) changes (e.g. specific locus test, mouse spot test).
In brief, ETU is regarded as weakly genotoxic because of the dose-dependent
increases of gene mutations observed in bacteria and the results of a few tests with
yeast cells, plants, fruit flies, mammalian cells and laboratory mammals (in vivo),
which have shown genotoxic effects at high exposure levels. Most in vivo tests
with mammals have been negative, however. N-nitroso ETU, on the other hand, is
a powerful genotoxin both in vitro and in vivo. Endogenous formation of N-
nitroso ETU, which occurs mostly in acidic environments, must be considered
when assessing both the genotoxicity of ETU and its potential carcinogenic effect.
The probability of N-nitroso ETU formation with ETU exposure must be much
lower with inhalation or skin uptake than it is with oral exposure.
Earlier assessments of genotoxicity
In 1987, the IARC summarized data from genotoxicity tests in the form of a
genotoxicity profile (32). Positive results were reported only from tests with
prokaryotes and lower eukaryotes. ETU was classified as non-genotoxic in an
assessment of pesticides made for a FAO/WHO program (20). The NTP reported
that ETU had been thoroughly tested for genotoxicity using numerous test
methods both in vivo and in vitro, and with few exceptions results had been
negative (66). DECOS, which set a health-based exposure limit for ETU (15),
reported that ETU per se is non-mutagenic. A 1995 review article described ETU
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as non-genotoxic in mammalian systems and proposed that ETU causes liver
tumors in mice by a non-genotoxic mechanism (18). Dearfield (at the EPA) made
the overall assessment that ETU could not be regarded as lacking genotoxic
activity (14). The genotoxic effect was judged to be weak, but it was pointed out
that nitrosation creates a mutagenic product that may be more potent.
Carcinogenicity
The results of cancer tests are summarized in Appendix 1. Most of these studies
were made with rats. Both short-term and long-term toxicity studies have shown
that species differ in both sensitivity to ETU and the organs affected.
Mice
Elevated incidences of hepatic adenomas and carcinomas have been reported in
mice at a dose of 66 mg/kg/day (330 ppm ETU in feed) (11, 66). Male and female
mice were exposed perinatally from minus one up to eight weeks of age (F0)
and/or as adults (F1) to between 0 and 1000 ppm ETU in feed. The mice exposed
to 330 ppm perinatally only showed no tumors after two years. Those exposed to
330 ppm as adults only had tumors in liver, pituitary or thyroid. For adult animals
exposed to 330 ppm, the incidences of thyroid and pituitary tumors were margi-
nally higher in animals that had also been exposed perinatally. Perinatal exposure
to 300 ppm, however, had no effect on tumor incidence in mice exposed to the
highest dose (1000 ppm) when they were compared to the group not exposed
perinatally.
Yoshida et al. (93) made a study in which ETU was given to mice (Crj:CD1) in
combination with sodium nitrite. The mice were given ETU and sodium nitrite (in
water) by gavage once a week for ten weeks, in the following combinations (ETU
+ NaNO2): 0 + 0; 100 + 0; 0 + 70; 25 + 17.5; 50 + 35 and 100 + 70 mg/kg body
weight. The animals were observed for 18 months beginning with the first treat-
ment. It was found that ETU combined with sodium nitrite caused an earlier
appearance of tumors and/or a dose-dependent increase of tumors in lymphatic
tissue, lung, stomach, Harder’s gland and uterus. The tumor locations were thus
not the same as those observed after administration of ETU alone (see 11, 66).
No carcinogenic effect was observed in mice given ETU or sodium nitrite alone.
A dose-dependent increase of pulmonary adenomas and adenocarcinomas was
observed in both females and males, and the number of females with pulmonary
adenomas or adenocarcinomas was significantly elevated in the group given (ETU
+ NaNO2 ) 25 + 17.5 mg/kg b.w./week. These results suggest that ETU is
transformed in vivo to N-nitroso ETU and that N-nitroso ETU has a stronger
carcinogenic effect on mice than ETU alone. This has been confirmed in a study
of tumor induction in mice (ICR females), in which oral administration of N-
nitroso ETU in doses of 0.66 to 2.64 mg (26.4 to 105.6 mg/kg b.w.) once a week
for ten weeks increased the incidence of pulmonary tumors and lymphocytic
neoplasms (62).
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Rats
For rats, the thyroid has been found to be the organ most sensitive to both short-
term and long-term exposures. Dose-dependent increases of thyroid tumors have
been observed in a number of different studies with rats (11, 23, 24, 26, 91, 92).
Graham et al. reported increased appearance of thyroid tumors at 250 ppm or
more in feed (24, 26), but not at 125 ppm. Calculating from information given by
the authors, exposure to 125 ppm in feed is equivalent to about 10 mg/kg body
weight/day (NOAEL). Gak et al. (23) reported no thyroid tumors after 20 months
of exposure to 17 ppm in feed (according to the authors, equivalent to 1.27 mg/kg
b.w./day or less).
In the NTP study, male and female rats were exposed perinatally from minus one
up to eight weeks of age (F0) and as adults (F1) to 0-250 ppm ETU in feed. There
was a clear increase of hyperplasia in thyroid follicular cells after 2 years of
exposure to 83 or 250 ppm. Thyroid follicular cell adenomas or carcinomas were
seen in about 20% of animals exposed to 83 ppm and in about 60% of those
exposed to 250 ppm. Male rats were more sensitive than females to the carcino-
genic effects of ETU. In addition to the dose-dependent increases of thyroid tumors,
there was also a small but significant increase of tumors in Zymbal’s glands (both
sexes at F0 90 ppm, F1 250 ppm) and mononuclear cell leukemia (both sexes at F0
90 ppm, F1 250 ppm; males at F0 90 ppm, F1 83 ppm) (11). The LOEL was 83 ppm,
which according to DECOS (15) is equivalent to 6.23 mg/kg b.w./day.
The ability of thioureas (e.g. ETU and thiourea) to cause thyroid tumors is
attributed to hormonal disturbances. Rats are regarded as a sensitive species in this
respect. Thiourea inhibits the enzyme thyroid peroxidase, which causes serum
levels of thyroid hormones T3 and T4 to decline. This in turn stimulates the hypo-
thalamus and pituitary, and more thyroid-stimulating hormone (TSH) is produced.
TSH stimulates thyroid growth, and chronically elevated levels of TSH in serum
can cause thyroid hyperplasia which may eventually develop into tumors (2, 27,
28).
When female rats were given simultaneous doses of ETU (80 mg/kg body
weight) and NaNO2 (56 mg/kg body weight) once per week from 11 to 51 weeks
of age, 13% of animals developed adenocarcinomas in uterine endometrium (65).
No such tumors were observed in controls.
Teratogenicity
ETU is strongly teratogenic to rats (10, 12, 41, 56, 72, 75). It can also have
embryotoxic effects on mice (10, 39), rabbits (41), cats (45), hamsters (10, 46),
and guinea pigs (10). ETU causes elevated mortality and a low incidence of
malformations in some of these species, but only at high dose levels (12, 40). In
an aquatic in vitro assay for embryotoxic effects on water fleas (Daphnia magna),
a significant increase in the incidence of malformations was seen at an ETU
concentration of 20 mg/liter (68).
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The lowest single oral dose that yields developmental anomalies in rats
(LOAEL) is 40 mg/kg body weight. For repeated doses, the lowest exposure is
10 to 20 mg/kg/day on days 6 to 15 of gestation (41, 72). Maternal toxicity was
observed at 80 mg/kg/day, and somewhat retarded ossification was observed in a
third of fetuses after repeated administration of 5 mg/kg (41). Brain damage is the
most common teratogenic effect in rats. ETU causes craniocele, meningo-
encephalocele, hydrocephalus, obliteration of the neural canal and enlarged brain
ventricles. Skeletal damage is also common, and includes club foot, short and
crooked tails, and rib anomalies. ETU shows different types of teratogenic effects,
determined by the stage of gestation at which the mother was exposed. It was
shown in one study (72) that effects on the eyes appeared only after treatment on
days 10 and 11, tail defects after treatment on days 11– 14, and cleft palate after
treatment on days 12-16. Damage to toes on forepaws appeared at earlier
exposures than damage to toes on hindpaws. In a study of teratogenic effects of
ETU in thyroidectomized females and controls given false thyroidectomies, it was
concluded that ETU-dependent changes in thyroid function or thyroxine levels in
the mothers was probably not the explanation for the teratogenic effects of ETU
(56).
Rat embryos examined after in vitro exposure to ETU show damage, primarily
to the tail and head, at concentrations of 10 mg/liter or higher (13, 35, 42, 89).
Both early (days 10-13) and late (day 19) prenatal exposure damages nervous
tissue (13, 40). Neural cells have been identified as particularly sensitive to the
toxic effects of ETU, both by examination of cells and tissues from exposed
embryos and by exposure of cultured embryonic cells (13, 40, 89).
For mice, the lowest single dose with embryotoxic effect (LOAEL) is
1600 mg/kg (39); for repeated exposures, the lowest dose level is more than
200 mg/kg (10). Rats are thus twenty to forty times more sensitive than mice,
although the teratogenic effects of ETU are of the same types in both species (13).
The difference in metabolic capacity between rats and mice leads to higher blood
levels of ETU in rats than in mice (see Biotransformation) (73). The effect of
maternal metabolism was examined by adding S9 from Aroclor-1254 induced rat
or mouse liver together with a NADPH-generating system to embryos exposed to
ETU in vitro (13). S9 from mouse completely neutralized the teratogenic effect of
ETU on both rat and mouse embryos. The differences in metabolism may explain
some of the differences in sensitivity between rats and mice, but rat embryos and
cultured brain cells from rats are also more sensitive to the toxic effects of ETU
than similar tissues from mice with exposure in vitro (13, 89).
Effects of nitrosation
In the presence of NaNO2 ETU is nitrosated to a substance that is teratogenic to
mice (87): 400 mg/kg ETU given together with 200 mg/kg NaNO2 is embryotoxic
and teratogenic, causing primarily skeletal anomalies when administered on day 6,
8, or 10, but not when administered on day 12 of gestation. The NaNO2 has effect
only when given within about an hour of the ETU exposure (87). The reported
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damage includes deformed tails and ribs, omphalocele, cleft palate, high
frequency of deformed vertebra, fused lung lobes, missing kidneys (kidney
agenesis), small or missing eyes and swollen brain ventricles (87).
N-nitroso ETU causes hydrocephalus in rat embryos (44). It has been observed,
however, that NaNO2 almost completely neutralizes the teratogenic effects of
ETU in rats treated on day 13 or 15 of gestation (43).
Dose-effect/dose-response relationships
It was found in one study that occupational exposure to ETU at air concentrations
in the range 120–160 mg/m3 inhibits thyroid function, measured as somewhat
lower levels of the thyroid hormone T4 (thyroxine). Levels of T4 were lower in
exposed workers (geometric mean 80.5 nmol/l) than in unexposed controls
(geometric mean 105.7 nmol/l), but the individual values were all within normal
reference limits for T4 (84). Assuming an air intake of 10 m3/day and a body
weight of 70 kg, exposure to an air concentration of 120 µg/m3 would result in
uptake of about 17 µg/kg/day. Skin uptake is likely, and may be high.
Elevated TSH levels were observed in Mexican farm workers exposed to fungi-
cides containing ETU. ETU levels in urine were on average 58 ppb (µg/liter) (85).
Assuming a urine volume of 2 liters, that half of absorbed ETU is excreted in urine,
and that uptake is complete, this is equivalent to a single dose of 3 to 4 µg/kg.
Considering the widespread use of ETU, there are few reported cases of contact
allergy.
Relevant information from animal experiments with oral exposure is summarized
in Table 1. In the only (unpublished) inhalation study with rats, effects on thyroid
were noted at exposure to 40 mg/m3 ETU 6 hours/day (3). If it is assumed that air
intake is 0.2 m3/day and body weight is 0.33 kg, this exposure is equivalent to
6 mg/kg/day. Exposure to 10 mg/m3 had no effect.
Conclusions
Data from occupational exposures indicate that the critical effect of occupational
exposure to ETU is its effect on the thyroid. This effect has also been observed in
experimental animals. ETU is carcinogenic to experimental animals. Simultaneous
exposure to ETU and nitrite in food yields tumors at lower ETU levels and in
other organs. ETU is considered to be slightly genotoxic, whereas N-nitroso ETU
is strongly genotoxic. ETU is teratogenic to experimental animals. The teratogenic
effect of ETU in different species seems to be inversely related to the biotrans-
formation rate. There are neither qualitative nor quantitative data on biotrans-
formation in humans. A few cases of contact allergy have been reported after skin
contact with ETU, but the allergenic potential of ETU is probably low. Animal
studies suggest that skin uptake may be high.
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Table 1. Effects observed in experimental animals given ETU in feed.
Dose
(mg/kg/day)
Concentration in
feed (ppm)
Duration of
exposure
Level value for effect, species,
effect
Ref.
0.2 - 0.4 5 24 months LOEL, rat
elevated serum cholesterol
23
0.4 - 0.7 5 20 months LOEL, hamster
elevated serum cholesterol
23
ca. 2 25 60 days LOEL, rat
effects on thyroid
22
ca. 2 25 90 days NOEL, rat
effects on thyroid
22
ca. 2 50 52 weeks LOEL, dog
effects on thyroid
20
3.7 50 120 days NOAEL, rat
effects on thyroid
25
3 - 4.3 60 13 weeks LOAEL, rat
thyroid hyperplasia
66
5 until day 15 of
gestation
LOAEL, rat
retarded ossification
41
6.2 83 24 months LOAEL, rat
thyroid cancer, effects on thyroid
11
10 until day 15 of
gestation
LOAEL, rat
teratogenic effects
41
10 20 days LOAEL, cat
CNS toxicity
45
23 28 days LOEL, rat
structural changes in renal tubules
50
66 330 24 months lowest tested dose, mouse
liver cancer, effects on thyroid
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Physical and chemical data. Uses
toluene-2,4-diamine (2,4-TDA)
CAS No.: 95-80-7
Synonyms: 2,4-diaminotoluene
1,3-diamino-4-methylbenzene
5-amino-o-toluidine
4-methyl-1,3-benzene diamine
2,4-toluenediamine
Formula: C7H10N2
Structure:
Molecular weight: 122.17
Melting point: 99 – 100 °C
Boiling point: 285 – 292 °C
Density: 1.042 g/ml
Flash point: 169 °C
Conversion factors: 1 ppm = 5.07 mg/m3 (20 °C)
1 mg/m3 = 0.19 ppm (20 °C)
CH3
NH2
NH2
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toluene-2,6-diamine (2,6-TDA)
CAS No.: 823-40-5
Synonyms: 2,6-diaminotoluene
1,3-diamino-2-methylbenzene
2-methyl-1,3-benzenediamine
2,6-toluenediamine
Formula: C7H10N2
Structure:
Molecular weight: 122.17
Melting point: 105 – 106 °C
Density: 1.031 g/ml
Flash point: 125 °C
Conversion factors: 1 ppm = 5.07 mg/m3 (20 °C)
1 mg/m3 = 0.19 ppm (20 °C)
At room temperature toluene-2,4-diamine (2,4-TDA) and toluene-2,6-diamine
(2,6-TDA) are clear crystals. Both substances are soluble in water (2,4-TDA: 37.8
g/l at 20 °C; 2,6-TDA: 60 g/l at 15 °C), alcohol, ether, and many polar solvents.
Both 2,4-TDA and 2,6-TDA are used primarily as intermediates in production
of diisocyanates and other chemical substances. They are also used in production
of urethane materials, paints and corrosion inhibitors. Some developing fluids
contain TDA. Persons exposed to 2,4- or 2,6-toluene diisocyanate have been
found to have 2,4-TDA or 2,6-TDA, respectively, in hydrolyzed urine (31). World
production of 2,4-TDA and 2,6-TDA in 1993 was reported to be about 650,000
metric tons (15).
Uptake, biotransformation, excretion
2,4-TDA can be absorbed via the skin and digestive tract. Skin uptake by humans
has been measured using 14C-2,4-TDA: 4 µg 2,4-TDA dissolved in acetone was
applied to the arm, and 24% of the dose was absorbed within 24 hours (29).
Excretion in urine was highest after 4 to 8 hours. Skin absorption varies
considerably, depending on the solvent used (21). It has been demonstrated in
studies with rats that 2,4-TDA (3 or 60 mg/kg) is absorbed in the digestive tract
and rapidly distributed to body tissues (42).
Rats were given 14C-2,4-TDA intraperitoneally (77 mg/kg i.p.), and 4 to 24
hours after the injection the highest concentrations of radioactivity were found in
liver and kidneys (18, 20). Mice were injected with the same substance (0.66
CH3
NH2NH2
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mg/kg i.p.), and 30 minutes later the highest tissue concentrations of radioactivity
were in kidney, testis, epididymis and lung; after 1 hour the concentration was
highest in liver (12% of the dose) (43).
In general, it appears that in most species only a small portion (0.1 to 3%) of
2,4-TDA is excreted unchanged, and the rest is metabolized (42, 44). The first
step is hydroxylation, followed by N-acetylation. Both mono- and diacetyl
derivatives have been identified in urine (3, 42, 44). The primary metabolite in
urine is 5-hydroxy-2,4-TDA, but mice and rats differ in the occurrence and
relative quantities of the various metabolites and conjugates (43). In vitro studies
have shown that N-acetylation occurs mostly in the liver (17). The reactive
metabolites are formed by P-450-dependent N-hydroxylation and sulfation (2,
12, 13, 20). It has been demonstrated in several studies that 2,4-TDA can form
adducts with DNA and hemoglobin (4, 11, 25, 27).
2,4-TDA is excreted rapidly, most of it in urine. In rodents, elimination is
biphasic: rapid elimination for 7 hours is followed by a slower phase (18, 43).
In a study with rats it was determined that in the slower phase the half time for
elimination in urine was 4.6 hours after intravenous administration (3 mg/kg)
and 8 hours after oral administration (3 mg/kg) (42). With intraperitoneal
administration (77 mg/kg, rats), 69% of the dose was recovered in urine and feces
within 24 hours (18). Chronic exposure has been found to increase elimination in
urine and decrease excretion in feces (43). 2,6-TDA can form hemoglobin adducts
(34, 47, 49).
2,6-TDA is rapidly absorbed in the digestive tract. It undergoes hydroxylation
and N-acetylation, and the primary metabolites found in urine are 2,6-diacetyl-
aminotoluene and 6-acetylamino-2-amino-3-hydroxytoluene (8). Rats given 10-
milligram oral doses of 14C-2,6-TDA eliminated 85% of the radioactivity in urine
within 24 hours. No unmetabolized 2,6-TDA was found in the urine. After 6 days,
1% of the radioactivity could still be detected in tissues (7).
Both 2,4-TDA and 2,6-TDA have been identified in hydrolyzed urine of
persons exposed to toluene diisocyanates (TDI), and there are some studies of
excretion of 2,4-TDA and 2,6-TDA by persons exposed to TDI (31). In one study
of TDI-exposed workers, the half time in urine was determined to be 18 days for
2,4-TDA and 19 days for 2,6-TDA, and the half time in plasma 7.8 days for 2,4-
TDA and 9.6 days for 2,6-TDA (28). In another study, in which volunteers were
exposed to TDI for 4 hours, the half time in plasma for 2,4-TDA and 2,6-TDA
was 2 to 5 hours during the initial elimination phase and more than 6 days in the
slower phase (5).
Toxic effects
Human data
There is no published information regarding effects on human health resulting
from exposure to 2,4-TDA or 2,6-TDA.
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Animal data
2,4-TDA
One published study reports that 2,4-TDA causes very little or no skin irritation
(14).
The reported LD50 values for 2,4-TDA range from 73 to 500 mg/kg body
weight, depending on species and method of administration. The reported LC50
values for inhalation exposure are 120 – 150 mg/m3 for mice and 916 mg/m3 for
rats (15). High doses of 2,4-TDA cause methemoglobin formation in several
species (37, 45). Cats were found to be the most sensitive species: a dose of 10
mg/kg (i.p.) resulted in elevated numbers of Heinz inclusion bodies (37), regarded
as an indication of oxidative stress.
Mice were given 2,4-TDA in oral doses of 25, 50 or 100 mg/kg/day for 14
days. The treatment resulted in changes in hepatic enzymes in serum, and the
highest dose resulted in higher liver weights. Immunotoxic effects – higher
numbers of B cells in spleens and lower spleen weights – were observed at all
exposures. The immunotoxic effects were attributed to disruptions in
differentiation and maturation of leukocytes (6, 46).
In a 7-week study, rats and mice were given 2,4-TDA in diet. The rats given
feed containing 1000 ppm 2,4-TDA (≈75 mg/kg body weight/day) had lower
body weights, elevated hematopoiesis and liver changes. The same diet given to
mice resulted in reduced body weights but no histopathological changes. The
NOEL for the 7-week exposure was reported to be 250 ppm for rats and 200 ppm
for mice (32). In a two-year NTP cancer study, groups of rats and mice were
given 2,4-TDA in diet for 103 weeks. Initial exposure levels for the rats were 125
and 250 ppm in feed, but because of low weight gain these amounts were reduced
to 50 and 100 ppm after 40 weeks. Elevated mortality was seen in the high-dose
group from 80 weeks onward. The histological findings included liver damage
and kidney changes (32). Exposure levels for the mice were 100 and 200 ppm
(≈15 and 30 mg/kg body weight/day), and liver hyperplasias and lower weight
gain were observed in both exposure groups (32).
2,6-TDA
The lethal single dose with oral administration was 3000 mg/kg body weigbt for
male rats and 1000 mg/kg b.w. for female rats (33). Rats exposed to 2,6-TDA in
diet (> 1000 ppm) for 14 days lost weight. There was elevated mortality among
mice given a diet containing 3000 ppm 2,6-TDA for 14 days. No effect was seen
on body weights of either rats or mice after 14 days on a diet containing 300 ppm
(33).
In a 13-week study, rats and mice were given 2,6-TDA in diet. Lower weight
gain was noted in male rats at 100 ppm (the lowest dose) and in female rats at
1000 ppm. This effect was also noted in mice, at 300 ppm for males and at 1000
ppm for females: 100 ppm had no effect on weight gain in the mice (33). The rats
developed thyroid hyperplasias at exposures of 3000 ppm or higher. Renal hyper-
pigmentation and a papilloma in the forestomach were observed in the mice at
29
1000 ppm (33). In a cancer study, rats were given 250 or 500 ppm and mice 50 or
100 ppm 2,6-TDA in diet for 103 weeks. Lower weight gain was registered for
the male rats in the high-dose group, the female rats in both dose groups, and the
female mice (33).
Genotoxicity
2,4- and 2,6-TDA have been found to be equally mutagenic in several in vitro
tests, including Ames’ tests. For a more detailed review of in vitro tests, reference
is made to the GDCH and IPCS documents (15, 23).
2,4-TDA
In vivo genotoxicity studies of 2,4-TDA have yielded positive results, especially
with high doses. A dose-dependent increase of single-strand breaks was observed
in the livers of rats after intraperitoneal administration of 2,4-TDA (37 – 500
mg/kg) (5, 22), although oral administration (50 or 150 mg/kg) had negative
results (24). An increase of unscheduled DNA synthesis was noted in rat hepato-
cytes after oral administration of 2,4-TDA (150 mg/kg) (16, 30). Intraperitoneal
administration of 2,4-TDA (9 or 18 mg/kg) increased sister chromatid exchange
in the bone marrow of mice (35). There have been some studies on the ability of
2,4-TDA to produce chromosome damage (15). Elevated frequencies of micro-
nuclei or chromosome aberrations have been seen in laboratory rodents only after
high doses. 2,4-TDA induced mutations in Big Blue™ transgenic mice (19, 38).
2,4-TDA given to rats induces dose-dependent increases in DNA adducts,
especially in liver and mammary glands. Three different types of DNA adducts
were identified, and 60% of the adducts remained two weeks later (25). The
lowest dose that induced DNA adducts in liver was 0.5 mg/kg (single dose, i.p.)
(4, 25). In another study, it was shown that an oral dose of 50 mg/kg yielded
greater numbers of adducts and more persistent adducts when administered over
10 days than when given all at once (27). The authors regard this as an indication
that activation of 2,4-TDA was saturated. It has been demonstrated that the
reactive metabolites are formed via P-450-dependent N-hydroxylation and
sulfation (2, 12, 13, 20), and the mutagenic intermediate of 2,4-TDA is believed to
be 4-acetoxyamino-2-aminotoluene (9). In a subsequent study with rats, adducts
were identified 6 months after 6 weeks of exposure to 40 or 180 ppm 2,4-TDA in
feed (11). In rats, 2,4-TDA has been shown to form covalent bonds to DNA, RNA
and microsomal protein, and to the microsomal fraction of liver (12, 15).
2,6-TDA
For 2,6-TDA, most in vivo mutagenicity studies have been negative. Positive
results are associated with extremely high doses (1).
2,6-TDA has been shown to give rise to hemoglobin adducts (34, 47, 49),
although no DNA adducts could be detected in rat liver after intraperitoneal
administration (150 mg/kg) (26). Both 2,4-TDA and 2,6-TDA have been shown
to form hemoglobin adducts in rats (single doses of 0.5 to 250 mg/kg, i.p.), but
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only 2,4-TDA induced DNA binding. When compared with 2,4-TDA, 2,6-TDA
showed about one third as much binding to hemoglobin and plasma protein, and
one third the tissue concentrations in liver and other organs (34).
Carcinogenicity
There are several older studies in which toluene diamines were tested for carcino-
genicity. These results have been summarized by the IARC (22), and the IARC
has classified 2,4-TDA as carcinogenic (Group 2B). In a later NTP cancer study
(32), groups of 50 rats were given 125 or 250 ppm 2,4-TDA dihydrochloride in
diet for 40 weeks. Levels were then reduced to 50 and 100 ppm due to toxicity,
and animals in the low-dose group were exposed for a further 63 weeks. Due to
the high mortality in the high-dose group, the animals were killed after 39 and 44
weeks. Dose-dependent increases were observed in the numbers of animals
(males and females) with hepatocellular carcinomas. An increase in the number of
animals with non-neoplastic changes was also noted. There were also elevated
numbers of females with carcinomas or adenomas in the mammary glands and
males with subcutaneous fibromas. In the same study, groups of mice were
exposed to 100 or 200 ppm 2,4-TDA in diet for 103 weeks. A dose-dependent
increase in hepatocellular carcinomas was seen in the females, and there was also
an elevated frequency of lymphoma among females in the low-dose group. No
significant increase of tumors was observed in the male mice (32).
2-6-TDA was tested in the same way (33). The dose levels tested were 200 and
500 ppm for rats and 50 and 100 ppm for mice. No significant increases in tumors
were observed.
2,4-TDA (25 mg/kg/day, p.o., 30 days) increased the growth of pre-neoplastic
foci in rat livers, whereas 2,6-TDA (50 mg/kg p.o., 30 days) was negative (39).
The difference in carcinogenic effect between 2,4-TDA and 2,6-TDA has been
discussed in the literature. No differences in absorption or metabolism have been
found that might explain it (8). The two substances have been found to be equally
mutagenic in several different in vitro tests. Results of in vivo mutagenicity tests
showed some differences, however, and 2,6-TDA was usually negative. Exposure
to 2,4-TDA in doses about the same as those used in the NTP study has also been
shown to increase cell proliferation in rat liver (10).
Teratogenicity
There have been several epidemiological studies addressing the question of
whether mixed exposure to toluene diamine and dinitrotoluene has teratogenic
effects. Teratogenic effects were found, but because of the mixed exposure these
studies are of no value in assessing the teratogenicity of 2,4-TDA (15).
Effects on spermatogenesis have been documented in several animal studies
with 2,4-TDA. They are ascribed to damage to Sertoli’s cells. In one study, rats
were given 2,4-TDA (15 mg/kg/day) in diet for 10 weeks. The treatment induced
degenerative changes in Sertoli’s cells and reduced spermatogenesis (48). In
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another study with rats, the same exposure resulted in lowered testosterone levels
and reduced spermatogenesis. The NOEL in this study was 5 mg/kg/day given in
diet for 10 weeks (40). The NOEL was the same for the fertility index of male rats
in another study (41). Mice were exposed to 2,4-TDA in a dominant-lethal test
(40 mg/kg i.p. or p.o for 2 days), and no effect on fertility was observed (36). A
dose of 150 mg/kg/day given to pregnant mice by gavage on days 7 to 14 of
gestation had teratogenic effects, but the dose was too toxic to the mothers to
allow the teratogenicity to be assessed (15). 2,6-TDA has not been tested for
teratogenicity.
Dose-response / dose-effect relationships
There are no data on which to base a dose-response or dose-effect relationship for
occupational exposure to 2,4-TDA or 2,6-TDA. The relationships between dose,
response and effect observed in laboratory animals are summarized in Table 1
(2,4-TDA) and Table 2 (2,6-TDA).
Conclusions
There are no studies of the effects of TDA on human health. In animal
experiments, the critical effect of 2,4-TDA is cancer. 2,4-TDA is a potent
carcinogen for experimental animals, with the liver as the primary target organ.
Dose-dependent increases of hepatocellular carcinomas have been observed in rats
and female mice. 2-4-TDA also affects the reproductive systems of male rats.
Both 2,4-TDA and 2,6-TDA are genotoxic.
There is no information that can be used to establish a critical effect for
occupational exposure to 2,6-TDA. 2,6-TDA has shown no carcinogenic effect in
animal experiments.
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Table 1. Effects observed in experimental animals exposed to 2,4-TDA. (NOEL = No
Observed Effect Level; c = control group; ld = low-dose group; hd = high-dose group).
Exposure Species Effect Ref.
in diet, 7 weeks
   1000 ppm (75 mg/kg/day) rat Reduced body weight, increased
hematopoiesis, changes in liver
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   250 ppm rat NOEL
   200 ppm mouse NOEL
in diet, 103 weeks
   125 or 250 ppm. 40 weeks;
   doses then reduced to
   50 or 100 ppm,
   (5.9 or 13 mg/kg/day)
   63 weeks (ld) and 39 or
   44 weeks (hd)
rat Reduced weight gain
Reduced weight gain, elevated mortality
(hd); hepatocellular carcinomas in females
(0/20 c; 0/50 ld; 6/49 hd) and males (0/20 c;
5/49 ld; 10/50 hd)
Mammary carcinomas or adenomas in
females (1/20 c; 38/50 ld; 41/50 hd)
Subcutaneous fibromas in males (0/20 c;
15/30 ld; 19/50 hd)
32
   100 or 200 ppm
   (15 or 30 mg/kg/day)
mouse Lower weight gain, dose-related increase of
hepatocellular carcinomas in females (0/19
c; 13/47 ld; 18/46 hd)
Lymphomas in females in low-dose group
(2/19 c; 29/47 ld; 11/46 hd)
32
p.o., single dose
   150 mg/kg rat Unscheduled DNA synthesis in hepatocytes 16, 30
p.o., 14 days
   100 mg/kg/day
   25 mg/kg/day
mouse Elevated liver weights
Immunological effects, changes in hepatic
enzymes
6, 46
i.p., single dose
   37 mg/kg rat Single-strand DNA breaks in liver 5, 22
p.o., 30 days
   25 mg/kg/day rat Increase of pre-neoplastic foci in liver 39
in diet, 10 weeks
   15 mg/kg/day rat Degenerative changes in Sertoli cells;
reduced spermatogenesis; lower testosterone
levels
40, 48
   5 mg/kg/day rat NOEL
i.p. single dose
   10 mg/kg cat Heinz inclusion bodies 37
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Table 2. Effects observed in experimental animals exposed to 2,6-TDA (NOEL = No
Observed Effect Level)
Exposure Species Effect/response Ref.
in diet, 14 days
   >1000 ppm
   300 ppm
rat Weight loss
NOEL
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in diet, 13 weeks
   3000 ppm
   (225 mg/kg/day)
rat Elevated mortality, thyroid hyperplasia 33
   1000 ppm rat Reduced weight gain (females)
   1000 ppm mouse Renal hyperpigmentation, papilloma in
forestomach.
Reduced weight gain (females)
in diet, 103 weeks
    500 ppm
    (24 mg/kg/day)
    250 ppm
    (12 mg/kg/day)
rat
rat
Reduced weight gain (both sexes)
Reduced weight gain (females)
33
in diet, 13 weeks
   100 ppm
   (7.5 mg/kg/day)
   100 ppm
   (15 mg/kg/day)
rat
mouse
Reduced weight gain (males)
NOEL
33
in diet, 103 weeks
   50 or 100 ppm
   (4.7 or 9.4 mg/kg/day)
mouse Reduced weight gain (females) 33
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Physical and chemical data. Uses
CAS No.: 98-83-9
Synonyms: 2-phenylpropene
isopropyl benzene
1-methyl-1-phenylethylene
2-phenylpropylene
α-methylstyrol
1-phenyl-1-methylethylene
1-methylethenylbenzene
Formula: C9H10
Structure:
Molecular weight: 118.19
Boiling point: 165 °C
Melting point: - 23.2 °C
Vapor pressure: 0.307 kPa (20 °C)
Flash point: 54 °C
Density: 0.91 g/cm3
Conversion factors: 1 ppm = 4.82 mg/m3
1 mg/m3 = 0.21 ppm
At room temperature α-methylstyrene is a clear liquid with a characteristic odor
(odor threshold: 0.1 mg/m3). It is soluble in benzene, diethylether, chloroform,
acetone and carbon tetrachloride (in acetone and carbon tetrachloride in any
proportions). It has an affinity for oils and fats (log Po/w = 3.34). Some t-butyl
catechol may be added to α-methylstyrene to prevent peroxide formation during
storage. Contact with heat or catalysts may cause α-methylstyrene to polymerize.
A common use for α-methylstyrene is as a solvent and polymer in plastic
production. It occurs in waxes, paints and other surface coatings.
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Uptake, biotransformation, excretion
Both pure α-methylstyrene and α-methylstyrene emulsified in water can be
absorbed through human skin. Undiluted α-methylstyrene (0.1 ml) spread on a
measured glass surface was pressed against the skin of 8 volunteers for 8 to 10
minutes. Both the glass and the skin were then washed with alcohol, and the α-
methylstyrene in the alcohol used for washing was determined with spectro-
photometry (244 nm). The absorption rate for α-methylstyrene in water emulsion
was determined by having 8 volunteers place their hands in 1-liter beakers of
emulsion. After 1 hour of exposure the amount absorbed was determined by
spectrophotometry. For undiluted α-methylstyrene, the absorption rate was
19.5 mg/cm2/hour. For α-methylstyrene in water the absorption rate varied with
concentration and temperature, and was 50% higher at 36 °C than at 24 °C (2).
Metabolism of α-methylstyrene is like that of styrene, its structural analogue. It
is activated by P-450 monooxygenase to α-methylstyrene oxide (7-methylstyrene-
7,8-oxide), and this metabolite is then transformed to α-methylstyrene glycol and
various glutathione conjugates. Oxidation of α-methylstyrene glycol yields α-
hydroxy-α-phenylpropionic acid (9), which has been identified in the urine of
persons exposed to α-methylstyrene by inhalation and animals exposed by
inhalation and intraperitoneal injection (1, 4, 5).
Toxic effects
Human data
Subjects (number not given) in an odor and irritation study were briefly exposed
(duration of exposure not given) to α-methylstyrene vapors in a test chamber. At
air concentrations of 2892 mg/m3 (600 ppm) or higher they reported a very strong
odor and experienced severe irritation of eyes and nose. A concentration of
482 mg/m3 (100 ppm) had a strong odor but did not cause excessive discomfort.
At an air concentration of 241 mg/m3 (50 ppm) the subjects reported a
pronounced odor but no irritation (15).
A change in the light sensitivity of the eye was observed in three odor-sensitive
persons after 15 to 20 minutes of exposure to a concentration of 0.1 mg/m3
(0.02 ppm) α-methylstyrene (odor threshold 0.1 mg/m3). These exposure condi-
tions also produced changes in the α-rhythm on their EEGs. Neither effect was
observed at 0.08 mg/m3 or 0.04 mg/m3 (10). These effects are not considered to be
toxicologically relevant.
There is a study describing a correlation between clinical symptoms of
poisoning and deterioration of renal circulation in 69 occupationally exposed
subjects employed in the production of divinyl-α-methylstyrene rubber. The
symptoms appeared after seven to eight years of employment. No further details
of this study were available (8). A case report describes workers handling divinyl-
α-methylstyrene rubber who developed ‘neurocirculatory dystonia’ as a result of
occupational exposure to 1,3-butadiene and α-methylstyrene. They also had some
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deterioration in liver function, but the cause of this is unclear. Further information
was not available (3).
Animal data
Effects of α-methylstyrene on skin were examined in a study with rabbits:
undiluted α-methylstyrene was painted on their ears and shaved rumps (10-20
strokes spaced over 2 to 4 weeks). The treatment resulted in moderate to marked
erythema as well as some necrotic effect in the form of exfoliation. In another
study, undiluted α-methylstyrene (two drops) was applied to the eyes of rabbits
and the eyes were examined after 3 minutes, 1 hour, 24 hours, 2 days and 7 days.
The substance caused slight inflammation of the conjunctiva, but no visible
damage to the cornea (15).
The LD50 for rats given α-methylstyrene per os was 4.9 g/kg. Liver damage was
found when the animals were dissected (15).
Mice were exposed to α-methylstyrene in air (2900, 3860 or 4800 mg/m3)
6 hours/day for 12 days. Mortality for the females was 6% (1/18) at 2900 mg/m3,
56% (10/18) at 3860 mg/m3, and 21% (5/24) at 4800 mg/m3. The cause of death
could not be determined. No male mice died during the exposures. During the
first hour of exposure the mice in all exposed groups were hyperactive and did not
react to noise. By the end of the 6-hour exposure the animals had calmed down
and appeared drowsy. The mice adapted to this ‘tranquilizing’ effect of α-methyl-
styrene after a week of exposure (5 days/week). Higher liver weights and lower
spleen weights were found in both males and females in all exposed groups. Liver
weights were significantly higher in the males after a single 6-hour exposure to
3860 mg/m3, and in the females after 5 days of exposure to 2900 mg/m3. After 5
days at 3860 mg/m3 reduced spleen weights were seen in both sexes. Only the
male mice had significantly lower body weights after 5 days of exposure. Histo-
pathological examinations revealed no exposure-related tissue changes. After 1
and 5 days of exposure there was a reduction of glutathione in the liver in all three
exposed groups (2900, 3860 and 4800 mg/m3) (9). In a short-term test, male mice
that inhaled α-methylstyrene had a higher threshold for seizures induced by
pentetrazole. A concentration of 3581 mg/m3 (743 ppm) α-methylstyrene caused a
50% seizure threshold increase (STI50) for pentetrazole (6).
In an inhalation study, exposure to 2900 or 4800 mg/m3 α-methylstyrene 6
hours/day for 12 days resulted in higher liver weights in F-344 rats. Hyalin drop
formation could be observed in the kidneys of F-344 males after nine days of
exposure to 1205 mg/m3 but could not be observed in F-344 females or male NBR
rats (which lack α2u-globulin production) under the same exposure conditions.
The effect is considered to be related to α2u-globulin, a protein that occurs in
much greater concentrations in male rats than in female rats. There was no hyalin
drop formation in the F-344 males exposed to 603 mg/m3 (9).
Histological examination of male white rats exposed to 5 mg/m3 α-methyl-
styrene 24 hours/day for 3 months revealed interstitial pneumonia, bronchial
inflammation (desquamative bronchitis), abnormal growth (hyperplasia) of
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bronchial lymph nodes, tissue changes in the walls of blood vessels, degenerative
changes in kidneys and heart muscles, disturbances of glycogen-related functions
in the liver (not explained) and neural cell dystrophy in the cortex, cerebellum and
spinal cord. After 2 weeks of exposure to 5 mg/m3 the rats had lower copropor-
phyrin levels in urine (not further elucidated) and a higher number of leukocytes
that showed abnormal coloration (green to yellow/yellow-orange) when dyed with
acridine orange (not explained). Only minor changes were observed in lungs, liver
and acridine-orange dyed leukocytes of rats exposed to 0.5 mg/m3 for 3 months,
and no effects were observed in rats exposed to 0.05 mg/m3 for 3 months (10).
Data in this study are inadequately presented and ‘end points’ are unclear.
In an inhalation study (15), Wistar rats (10 to 25 per group, both sexes) were
exposed to α-methylstyrene concentrations of 970 mg/m3 (for 139 7-hour
sessions), 2900 mg/m3 (for 149 x 7 hours), 3860 mg/m3 (28 x 7 hours) or
14,490 mg/m3 (for 3 or 4 x 7 hours) (= 200, 600, 800 or 3000 ppm). The exposure
to 14,490 mg/m3 resulted in high mortality (not quantified). The group exposed to
3860 mg/m3 lost weight, and kidney and liver weights were affected (no quantita-
tive data given). Effects on kidney and liver weights were also observed at
2900 mg/m3. No effects were observed at 970 mg/m3.
Guinea pigs were exposed according to the same protocol. Those exposed to
3860 mg/m3 lost weight, and liver and kidney weights were affected. Liver weight
was affected at 2900 mg/m3. No effects were seen at 970 mg/m3. Rabbits were
exposed to 970 mg/m3 (139 x 7 hours) or 2900 mg/m3 (149 x 7 hours). The lower
dose group showed no effect. In the higher dose group the exposure resulted in
higher mortality and weight loss. Rhesus monkeys (1 or 2) of both sexes were
exposed along with the rabbits, and neither exposure level resulted in observable
histopathological changes or effects on organ weight (15).
Mutagenicity, carcinogenicity, teratogenicity
Ames’ tests with α-methylstyrene were negative, both with and without metabolic
activation (16), although the intermediate metabolite α-methylstyrene oxide has
yielded positive results (14). Sister-chromatid analysis of human lymphocytes in
vitro revealed a significant increase in the frequency of sister chromatid
exchanges (11). Unlike styrene, which is activated by hemoglobin, α-methyl-
styrene’s ability to induce sister chromatid exchanges is not dependent on
erythrocytes (11, 12, 13).
Methylstyrene (unspecified isomer) was tested for teratogenicity in a study with
rats: 250 mg/kg body weight (in corn oil) was injected intraperitoneally. The
treatment had no observed effect on the mothers, but there were changes in the
sex ratio of the embryos (fewer females) and a significantly higher frequency of
resorptions (7).
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Table 1. Some effects observed in laboratory animals exposed by inhalation to α-
methylstyrene.
Exposure level
(mg/m3)
Duration Species Effect Ref.
 970 139 x 7 hours rat
(Wistar)
NOEL 15
2900 149 x 7 hours rat
(Wistar)
Changes in kidney and liver weight
LOEL
15
2900 6 hours mouse
(B6C3F1)
Glutathione reduction in liver
LOEL
 9
2900 12 x 6 hours rat
(F344)
Elevated liver weight  9
NOEL = No Observed Effect Level
LOEL = Lowest Observed Effect Level
Dose-response / dose-effect relationships
Brief exposure to 482 mg/m3 (100 ppm) α-methylstyrene in air produced
symptoms of irritation in eyes and respiratory passages of subjects in an exposure
chamber (LOEL). At 241 mg/m3 (50 ppm) the odor was apparent but no symp-
toms of irritation were noted (NOEL). There are no other data on human expo-
sures that can be used as a basis for describing a dose-effect or dose-response
relationship. Dose-response and dose-effect relationships observed in animal
experiments are given in Table 1. Preliminary data indicate that α-methylstyrene
may be fetotoxic.
Conclusion
The critical effect of exposure to α-methylstyrene is irritation of eyes and mucous
membranes These effects were observed in subjects briefly exposed to 482 mg/m3
(100 ppm) in a test chamber, but this study provides no information on which to
base a NOEL for occupational exposure to α-methylstyrene.
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Sodium Cyanide and Potassium Cyanide
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Chemical and physical data. Uses
hydrogen cyanide
CAS No.: 74-90-8
Synonyms: hydrocyanic acid, prussic acid, formonitrile
Formula: HCN
Molecular weight: 27.04
Boiling point: 25.70°C
Melting point: -13.24°C
Vapor pressure: 83.8 kPa (20°C)
Saturation concentration: 827,246 ppm
Conversion factors: 1 mg/m3 = 0.89 ppm (20°C)
1 ppm = 1.12 mg/m3 (20°C)
sodium cyanide
CAS No.: 143-33-9
Synonyms: cyanide of sodium
Formula: NaCN
Molecular weight: 49.01
Boiling point: 1496°C
Melting point: 563.7°C
Vapor pressure: -
potassium cyanide
CAS No.: 151-50-8
Synonym: cyanide of potassium, cyanide of potash
Formula: KCN
Molecular weight: 65.12
Boiling point: -
Melting point: 634.5°C
Vapor pressure: -
44
HCN occurs as a colorless gas or as a clear, extremely volatile and flammable
liquid. It has an odor of bitter almonds. It is soluble in ethanol and similar
solvents and mixes with water, forming a weak acid (4, 44). One source reports an
odor threshold of 0.2-5 ppm for HCN (21), but there are many people who can not
perceive the odor at all (39, 40). NaCN and KCN occur as clear or whitish solids
(4). They are readily soluble in water (about 50 g/100 ml cold water), producing
strongly alkaline solutions (59, 68).
Occupational exposure to cyanide can occur during industrial production and
use of cyanide compounds, and may also result from exposure to industrial
chemicals that are metabolized to cyanide, such as simple aliphatic nitriles (4).
Cyanides also occur naturally in many foods (e.g. cassava/manioc, passionfruit,
bamboo shoots, bean sprouts and almonds, and the pits of apricots, peaches,
cherries and plums) in the form of cyanogenic glycosides, which can be broken
down to HCN in the intestine (4, 34, 46). Cyanide may occur in foods as pesticide
residue (4, 34). Cyanide exposure may also have several other sources, including
tobacco smoke, smoke from fires, vehicle exhausts and some medicines (4, 34).
Cyanides are used primarily in the steel, mining, and chemical industries and in
electroplating (4). NaCN is used, for example, to extract gold and silver from ore
and in the production of adiponitrile (for nylon), pigments, chelating agents and
pesticides (34, 40). NaCN and KCN are used together to treat steel. Large
amounts of cyanide salts such as NaCN and KCN are used in electroplating –
KCN particularly with silver plating (4, 34). Many metal polishes contain NaCN
or KCN. HCN is used in the production of adiponitrile (for nylon), methylmeth-
acrylate, NaCN, chelating agents, and pharmaceuticals. HCN may also be used to
fumigate grain storage facilities to kill rodents and insects (4).
Uptake, biotransformation, excretion
HCN, NaCN and KCN are rapidly absorbed in the intestine (4, 6, 73). HCN is also
taken up very rapidly by the lungs (4, 6). Monkeys were exposed by inhalation to
100-150 ppm HCN, and a constant blood level was reached within about 10
minutes (67). In an older study, volunteers were exposed to 0.5-18 ppm (0.5-
20 mg/m3) HCN by breathing through the mouth. Samples were taken from the
start of exposure for up to about 3 minutes, and lung retention was calculated to
be about 40-80% (about 60% with ‘normal’ breathing). The results were not
concentration-dependent (52). When volunteers were exposed to 1-10 ppm (1.1-
11 mg/m3) HCN by breathing through the nose, retention was reported to be 13-
23% regardless of concentration (52). Uptake of NaCN and KCN via the lungs is
probably also quite high, but no studies or estimates were found.
Skin uptake varies. In a study with rabbits, application of NaCN dust to dry,
intact skin was reported to result in absorption of amounts too small to produce
indications of systemic toxicity. Damp NaCN (paste), however, and HCN, NaCN
or KCN in solution, were rapidly absorbed through intact skin in amounts
sufficient to cause deaths (6). In vitro studies (20) have revealed that the
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absorption rate of NaCN in aqueous solution is strongly dependent on pH in the
interval 9-12. The steady-state absorption rates of CN (pH 11.2-11.4) with
application of a 1%, 10%, or 40% solution of NaCN were reported to be 2.3, 58
and 62 µg/cm2/hour, respectively. These studies also showed that HCN is rapidly
absorbed through the skin. The reported permeability constant for the cyanide ion
was 3.5 x 104 cm/hour, and that for HCN 100 x 104 cm/hour (in aqueous solution).
This means that, at steady-state, HCN is absorbed 30 times faster than CN (20).
After uptake, cyanide is reversibly bound to the methemoglobin in red blood
cells and efficiently distributed by the blood throughout the body (4, 14, 73). The
total binding capacity of methemoglobin at normal physiological levels has been
reported to be about 8 mg HCN (73). The cyanide that is not bound to methemo-
globin is metabolized in various tissues, notably the liver, kidneys and nasal
epithelium (6, 12, 14, 31, 55). Several biotransformation pathways have been
identified (Figure 1). The main one involves enzymatic transsulfurization to
thiocyanate (6, 46, 88). The detoxification rate in humans after intravenous
administration of HCN is reported in one work to be 0.017 mg CN/kg body
weight/minute (McNamara 1976, cited in 6; 24, 53). In a pharmacological paper,
however, it is reported that the maximum detoxification rate for cyanide in
humans is only 0.6 to 0.9 µg/kg body weight/ minute, and that the earlier
assumption that the human body can transform 0.017 mg CN/kg body
weight/minute is erroneous (74). This author also reports that the detoxification
rate is considerably lower in humans than in laboratory rodents or dogs (73).
Access to a sulfur substrate (especially thiosulfate) usually determines the speed
and efficiency of the transformation of cyanide to thiocyanate (6, 12, 31, 46, 74).
It has been reported that metabolism of cyanide is affected by nutrient
imbalances, especially protein deficiency (13, 74, 82).
Most absorbed cyanide is excreted in urine, primarily as thiocyanate, but small
amounts are also eliminated in urine and exhaled air as HCN, carbon dioxide and
other biotransformation products (6, 56, 60, 90). The average half time for
excretion of thiocyanate has been reported to be 2.7 days in healthy subjects and
9 days in subjects with renal insufficiency (73). The portion excreted in human
urine as thiocyanate has been found to be many times larger than the portion
detected in urine as cyanide, with both ‘normal’ exposure (via food, tobacco
smoke etc.) and occupational exposure (15, 57). Smokers excrete much more
thiocyanate in urine than non-smokers do (15).
A correlation between air concentration of cyanide and excretion of thiocyanate
in urine was determined in a study: the amount of thiocyanate in urine (24-hour
samples) = 0.65 x air concentration of cyanide (ppm) (22). “Air concentration”
refers to the average concentration of cyanide in the air for the last three days of
the work week, and the correlation applies to the average concentration of
thiocyanate in urine during the same period.
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Toxic effects
Human data
In cases of acute cyanide poisoning the primary target organs are the central
nervous system and the heart (4). The toxic effects of cyanides are attributed
primarily to the (reversible) formation of complexes with the Fe3 ion in the enzyme
cytochrome c oxidase, which compromises the cells’ ability to exploit oxygen (4, 6,
8, 30, 34, 39). Cyanides also inhibit many other enzyme systems, however, and
these reactions contribute to the classic symptoms of acute cyanide poisoning (4,
6). The indications of acute cyanide poisoning include rapid breathing, dizziness,
confusion, headache, nausea, vomiting, atony, ataxia, dyspnea, cardiac arrhythmia,
convulsions, coma and death (32, 34, 64, 89). With lower exposures, symptoms of
acute cyanide poisoning may appear after accumulation of cyanide (6).
There are numerous reported cases of acute and sometimes fatal poisoning due
to oral intake of cyanides in various contexts. The lowest fatal dose (absorbed
dose) for oral intake of single doses by humans has been calculated to be about
0.5 mg HCN/kg body weight (29) . Acute poisoning has also been observed after
skin exposure to very high air concentrations of HCN or to HCN in liquid form
(20, 65, 75). In one case, dizziness, breathing difficulty and loss of consciousness
were reported within three to five minutes after HCN had been spilled on the
patient’s hand (65). Deaths have been reported following acute inhalation ex-
posure to relatively high air concentrations of HCN (see Table 1).
Systemic effects, notably on the nervous system, digestive tract and thyroid,
have been reported after repeated occupational exposure to cyanides (7, 11, 22,
32, 72). In some cases the symptoms involving the nervous system and digestive
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Figure 1. The primary metabolic pathways for cyanide (adapted from Reference 3).
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tract took some time to appear, and it is not clear whether this represents a chronic
form of cyanide poisoning or acute effects. Thyroid hypertrophy has been
associated with chronic exposure to cyanides and seems to be related to the
thiocyanate ion (4, 33). Cyanides are also suspected of contributing to the
deterioration of vision observed in some smokers (tobacco amblyopia), especially
those with high alcohol consumption and nutritional deficiencies (26, 27, 70, 78).
Neurological effects and effects on the thyroid have been documented after
prolonged consumption of foods containing cyanogenic glycosides. Outbreaks of
konzo, a distinct form of tropical myeloneuropathy characterized by abrupt onset
of incapacitating spasms, have been reported in populations in Africa after periods
when the diet consisted mostly of cassava. Another cassava-related neural disease
is tropical atactic neuropathy. It usually develops gradually over the course of
several years (41, 62, 79, 82, 83). Another disease that has been associated with
high and prolonged cassava intake is goiter, which appears primarily in
conjunction with low iodine intake (1, 2, 16).
In a retrospective study made in the United States, symptoms of cyanide
poisoning were seen in factory workers (n = 36) who had been exposed to cyanide
(NaCN, HCN) during a silver reclaiming process (11). The workers had been
exposed to cyanides via inhalation, skin contact and possibly also oral intake. The
average air content of HCN one day after the factory had been closed (24-hour
measurement) was 15 ppm. More than two thirds of the workers reported on a
questionnaire that they had experienced headaches, dizziness, nausea/vomiting,
and/or a bitter taste in the mouth on more than 10 occasions per month. Other
reported symptoms included eye irritation, loss of appetite, weight loss, nose-
bleeds, fatigue, skin rashes, heavy perspiration, shortness of breath, cough, sore
throat, chest pains, changes in the sense of smell, coughing up blood, heart
palpitations and fainting. There was a correlation (significant positive trend)
between exposure level and the subjects’ assessments of the severity of the
poisoning, but the exposure estimate was not connected to the air measurements.
Some symptoms were reported to last for seven or more months after exposure
had been terminated (lower prevalence). Biochemical analyses made more than
half a year after exposure had stopped revealed somewhat higher average values
of thyroid-stimulating hormone (TSH) in serum (high-exposure group 2.4 µU/ml,
laboratory control average 1.7 µU/ml) and somewhat fewer free bonding sites on
thyroxine-binding globulin (TBG) in serum (T3U test: high-exposure group
32.4%, laboratory control average 30.0%). On the other hand, values for the
thyroid hormone T4 (thyroxine) were normal and there were no palpable changes
in thyroids. The exposed workers (particularly those with high exposure) also had
lower average levels of vitamin B12 and folic acid in serum. The results are
interpreted by the authors as possible indications of effects of long-term cyanide
exposure (11).
In another epidemiological study, 36 Egyptian workers (non-smokers) who had
been exposed to cyanide for 5 to 15 years of working with a plating bath containing
3% NaCN and 3% copper cyanide were compared with 20 controls (22). Head-
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aches, weakness, changes in the senses of taste and smell, dizziness, throat
irritation, vomiting, shortness of breath with physical exertion, watery eyes, chest
pains and several other symptoms were reported more frequently by the exposed
workers than by controls. Two of the nine workers from the factory with the
highest exposure levels (8.2-12.4 ppm) were reported to have suffered psychotic
episodes. Slight to moderate thyroid enlargement was seen in 20 of the exposed
workers, but none of them had clinical indications of hypo- or hyperthyroidism.
Changes in blood profile, including significantly higher hemoglobin levels and
lymphocyte counts, were also noted in the exposed workers. The workers were
given radioactively labeled iodine after two days away from work, and much
higher iodine concentrations (p <0.001) were found in the thyroids of the cyanide-
exposed workers than in controls [average values for exposed workers: 38.7%
(4 h), 49.3% (24 h); averages for controls, 22.4% (4 h), 40% (24 h)]. There was no
significant difference for iodine bound to protein in blood (131PBI) after 72 hours.
Air concentrations of cyanide in the breathing zone of exposed workers (15-minute
samples) ranged from 4.2 to 12.4 ppm (average concentrations 6.4-10.4 ppm). The
concentration of thiocyanate in urine increased gradually, and during the last three
days of the work week it was virtually constant and strongly correlated to the
average air concentration of cyanide (22).
In an Indian study (7), serum from 35 workers who handled cyanide salts in a
cable industry (electroplating) and 35 matched controls was analyzed for evidence
of effects on thyroid function. All subjects were non-smokers. No information on
air concentrations is given. The content of thiocyanate in serum was higher in the
exposed group than in the controls. The exposed workers had significantly lower
serum levels (p <0.05) of thyroid hormones T4 and T3, and significantly higher
levels (p <0.05) of TSH, than the controls. In the exposed group there was also a
significant positive correlation between serum levels of TSH and thiocyanate
(p <0.05) and a significant negative correlation between T4 and thiocyanate
(p <0.05). According to the authors, these results indicate that occupational
exposure to cyanide may inhibit thyroid function (7).
Another Indian study (15) reports that symptoms characteristic of cyanide
poisoning were observed in 23 workers exposed to HCN gas and cyanide aerosol
during case-hardening and electroplating operations. The workers had elevated
levels of cyanide and thiocyanate in blood and urine, but no details on their other
symptoms are given. The measured cyanide levels in the breathing zone were in
the range 0.1-0.2 mg/m3 (0.09-0.19 ppm), and measurements made on the shop
floor yielded values in the range 0.2-0.8 mg/m3 (0.19-0.74 ppm). The limited
information in this report provides insufficient basis for any conclusions regarding
a relation between effects on health and air concentrations of cyanide.
Significantly elevated serum values for zinc, calcium and iron were found in a
study of women who reportedly were exposed to HCN and cyanides 8 hours/day
at work (37). The same authors report in another study that significantly elevated
serum values for L-aspartate-2-oxyglutarate-aminotransferase (SGOT) and lactate
dehydrogenase (LDH) were found in women (probably at the same workplace)
49
who reportedly were exposed to vapors of HCN and cyanides 8 hours/day (38). In
both studies, the authors interpret the findings as effects of cyanide exposure. It is
also reported that on a few occasions the threshold limit of 5 mg HCN/m3 was
exceeded, air concentrations (calculated as HCN) then reaching a maximum of
7.5 mg/m3. No details of the measurements are given, however. There is little
information on other occupational exposures or any differences in food intake
between the exposed group and controls, and the interpretation of the results must
therefore be regarded as uncertain.
It is reported in a reference work (23) that a mist of an alkaline solution
consisting mostly of NaCN caused severe nasal irritation and in some cases
erosion of the nasal septum in occupationally exposed persons, and that the air
concentrations of cyanide (expressed as HCN) had not been much above 5 ppm. It
is suggested, however, that these persons may have been exposed to other alkaline
substances that may have contributed considerably to the observed irritation.
Skin contact with NaCN or KCN can cause severe skin irritation as well as
systemic toxicity (6, 40). The skin irritation is probably due to the alkalinity of the
substances.
Animal data
HCN, NaCN and KCN are extremely toxic. With oral intake, the reported LD50
for all three substances is between 2.5 and 16 mg/kg body weight (rabbit, rat,
mouse). For skin application of solutions (intact skin of rabbit), the reported LD50
is 6.9 mg/kg b.w. for HCN, 14.6 mg/kg b.w. for NaCN, and 22.3 mg/kg b.w. for
KCN (6, 24). With inhalation exposure, the LC50 for HCN varies with species and
exposure time, but in some studies (rabbit, rat, mouse) has been reported to be
about 110-170 ppm for 30 minutes of exposure, about 320-500 ppm for 5 minutes
of exposure, and about 1000-3400 ppm for exposures of 1 minute or less (6, 54,
58, 86).
Inhalation exposure to HCN affects most prominently the central nervous
system (Table 2). Hyperventilation, grogginess and slow, irregular heartbeat, and
in many cases cramps or apnea were observed in a study in which monkeys were
exposed to 100-156 ppm HCN for up to 30 minutes. At an air concentration of
100 ppm it took 19 minutes for the animals to become so affected that they were
unable to move (67). A slight dampening effect on the CNS was observed at an
exposure to 60 ppm HCN (monkeys, 30 minutes). EEG changes (including
increased delta and theta activity) and reduced amplitude in measurement of
auditory cortical evoked potential could be observed toward the end of the
exposure period. Some increase in respiratory minute volume was also noted.
There were no significant effects on heart/vascular parameters, peripheral
neuromuscular impulse transmission, or neural transmission speed (66). Reduced
respiratory minute volume, respiratory rate and pulmonary compliance, and lower
phospholipid levels in the lungs (surfactant), were reported in another study in
which rats were exposed to 55 ppm HCN for 30 minutes. Increased transthoracic
pressure, air flow and tidal volume were also observed (9). In a study with mice,
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the DC50 (50% reduction of respiratory rate due to effects on the respiratory
center) for 30 minutes of exposure to HCN was calculated to be 63 ppm.
Intermittent sensory irritation was also observed (58).
A French study (85, cited in 4) reports observations of dyspnea, vomiting,
diarrhea, tremor, spasms, ataxia and coma in dogs that had been exposed to
45 ppm HCN 30 minutes/day for 28 to 96 days. Histological changes in the brain
were also observed. In an older study with several species, at exposure to 45 ppm
HCN the animals fell and remained lying on their sides within 15 to 30 minutes
(25). In a study with rabbits in which heart, lungs and associated arteries were
studied, no treatment-related effects were reported after constant exposure to
about 0.5 ppm HCN for up to 4 weeks (42, 43).
Effects on the central nervous system/behavior, thyroid, kidneys and reproduc-
tive organs have been reported after repeated exposure by means other than
inhalation (Table 3). One study describes degenerative changes in the central
nervous system and inflammatory changes in the digestive tract in two dogs given
0.5 or 2 mg NaCN (= 0.27 or 1.1 mg CN) /kg body weight/day in gelatin capsules
for 13.5 or 14.5 months. Symptoms of acute toxicity were sometimes noted in
conjunction with administration (36). In another study, pigs were given an
aqueous solution of KCN by gavage for 24 weeks. Doses were equivalent to 0.4,
0.7 or 1.2 mg CN/kg body weight/day. There was a gradual reduction in blood
levels of T3 and to some extent also T4 in all dose groups (especially the high-dose
group), and progressive, dose-dependent increases of blood glucose (fasting
values) and effects on behavior were also noted (45). Kidney damage (nephrosis),
indications of hyperplasia/hypertrophy of adrenals (zona glomerulosa) and effects
on testes (see Effects on reproduction) were observed in histopathological
examination of dogs after 14 weeks on a diet containing NaCN in an amount
equivalent to 1.04 mg CN/kg body weight/day (47). In earlier studies by the same
author, dogs fed on this diet for 14 weeks developed hypothyroidism and goiter,
and there were also effects on the pancreas (necrosis, fibrosis, atrophy) (48, 49).
In an NTP study (34), NaCN mixed in the drinking water of rats and mice in
amounts ranging from 3 to 300 mg/l (rats: about 0.16-13 mg CN/kg b.w./day;
mice: about 0.3-27 mg CN/kg b.w./day) for 13 weeks caused changes in various
reproduction parameters (see Effects on reproduction). Other observations
included lower water consumption, especially in the higher dose groups, but there
were no clinically significant changes in body weight, organ weight, or hemato-
logical or clinical-chemical parameters, and no histopathological changes in
examined organs (including thyroid, brain, adrenals, kidneys, liver, heart and
lungs).
Cyanides can irritate the eyes. Local effects observed in eyes of rabbits after
instillations of HCN, NaCN and KCN were inflammation, gradual swelling of the
conjunctiva, and cloudiness of the cornea (5, 6). Severe symptoms of poisoning
were also noted after concentrated solutions had been applied to the eyes (5).
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Mutagenicity, carcinogenicity
HCN was mutagenic to the Salmonella typhimurium strain TA100, but not TA98.
The mutagenic activity was reduced by metabolic activation (51). NaCN and
KCN were reported to be non-mutagenic to strains TA97, TA98, TA100,
TA1530, TA1535, TA1537, TA1538 and/or TA1950 both with and without
metabolic activation (17, 18, 34, 50, 69). KCN, however, was positive in a DNA
repair test with E coli (18). KCN induced chromosomal aberrations when tested
on mammalian cells in vitro, and higher doses induced DNA fragmentation (10,
84). In vitro studies with human cells indicate that KCN is cytotoxic but not
genotoxic (35, 87). Inhibited DNA synthesis, but no DNA damage, was reported
in an in vitro DNA-synthesis inhibition test (KCN) using HeLa cells (63).
However, inhibition of DNA synthesis (testes) was not observed in vivo after
oral administration of 2.5 mg KCN/kg body weight to mice (28).
No studies specifically of carcinogenicity were found in the literature. In one
study in which rats were given extremely high amounts of KCN in diet – 50 or
100 g/kg feed (sic!) – for 14 weeks (61), benign tumors were found in cecum and
large intestine (7/10 animals in the high-dose group; 5/10 animals in the low-dose
group; results in controls not reported). The tumors consisted of many hyper-
trophic muscle fibers with no indication of malignancy. Other observations
included reduced body weights, lower relative spleen weights, higher relative
thyroid weights, hepatic cell necroses and hematological /biochemical changes.
Effects on reproduction
Hamsters were given slow infusions of NaCN from subcutaneous implants
liberating 6.18 to 6.35 mg/kg b.w./hour, equivalent to about 148-152 mg/kg
b.w./day (total doses more than 30-40 times the LD50), on days 6 to 9 of gestation.
There were signs of toxicity in the mothers, especially at the higher dose, and high
incidences of severe malformations and resorptions at all dose levels (19). An
abstract (76) reports inhibited growth, meningoceles/myeloceles and some deaths
in embryos of rats given daily intraperitoneal injections of KCN (aqueous
solution) during the first 15 days of gestation (3 mg/kg b.w. per injection).
In an experiment in which rats were given NaCN by gavage (6 mg/kg b.w. in
water) on day 10 of gestation, morphological anomalies were noted in some
fetuses 48 hours after the administration. Clinical indications of toxicity
(including deaths) were observed in the mothers (71). In studies in which
pregnant pigs and rats (80, 81) were fed on cassava containing up to 1250 mg
KCN/kg, the only observed toxic effects on reproduction were minor metabolic
differences and lower relative organ weights in fetuses at doses affecting the
mothers.
In an NTP study, mice and rats were given drinking water containing 30, 100 or
300 mg NaCN/liter (rats: about 1.6-13 mg CN/kg b.w./day; mice: about 3-27 mg
CN/kg b.w./day) for 13 weeks, and examined for effects on various reproduction
parameters (reproductive toxicity at lower doses was not studied). Effects were
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particularly evident in the rats, but were judged by the authors to be “probably
insufficient to decrease fertility in rats.” Significant, dose-dependent reductions of
cauda epididymal weight (all dose groups) and dose-dependent reductions (signi-
ficant in the high-dose group) of epididymis and testis weights were observed in
rats. Cauda epididymis and epididymis weights were significantly lower in the
high-dose group of mice. The number of sperm per testis was significantly lower in
the high-dose group of rats. Sperm motility was also lower in the rats (all dose
groups), but this was judged to have no biological significance. Altered estrus
cycles were observed in female rats in the two higher dose groups, but no effects on
estrus cycle were seen in the female mice (34). Effects on spermatogenesis
(significantly lower relative frequency of stage 8 tubuli and degenerative changes
with elevated occurrence of abnormal gametes) were observed in testes of dogs
given food containing NaCN (dose equivalent to 1.04 mg CN/kg b.w./day) for
14 weeks (47).
Dose-effect/dose-response relationships
There are few reliable measurements of air concentrations of HCN, NaCN or
KCN in an occupational exposure context. In most of the studies that report air
concentrations, exposure to cyanide by other means (such as skin uptake) can be
suspected, and it is therefore difficult to determine dose-response relationships
with certainty. There is the additional problem of mixed exposures. Irritation of
respiratory passages and toxic symptoms indicating effects on the central nervous
system have been reported in several studies, however. Effects on the thyroid
have also been noted after exposure to HCN and cyanide salts, and have been
presented as possible long-term effect of exposure. One work (22) reports that
effects on the central nervous system (including two psychoses, headache,
vomiting, dizziness, weakness, changes in the senses of taste and smell) were
more common among exposed persons than among controls, and that the
measured air concentrations of cyanide in the breathing zones of the exposed
workers (15-minute samples) ranged from 4.2 to 12.4 ppm (average concen-
trations 6.4 to 10.4 ppm). Effects on the thyroid were also noted at these air
concentrations (Table 1). There are no data indicating skin uptake of cyanide in
this study.
The maximum detoxification rate for cyanide in humans, as calculated from
information on infusions of medicine given to acutely ill patients, is about 60 µg
CN/minute (74). Assuming that inhaled air amounts to 20 l/minute and uptake is
100%, this detoxification rate corresponds to uptake from inhalation exposure to
about 3 mg/m3. This calculation indicates that at higher exposure levels there may
be an accumulation of cyanide in the body, and it can therefore be assumed that
about 6 hours of constant exposure to 4 mg/m3 might give rise to cyanide levels in
the blood that can yield biochemically detectable metabolic disturbances.
Dose-effect relationships observed in animals experimentally exposed to HCN,
NaCN and KCN are summarized in Tables 2 and 3. Effects on the brain have been
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observed at daily oral doses of 0.5 mg NaCN/kg b.w. (equivalent to 0.27 mg
CN/kg b.w.), and effects on behavior and/or thyroid hormones have been noted
with daily oral doses of 1 mg KCN/kg b.w. (equivalent to 0.4 mg CN/kg b.w.)
(36, 45). Lower doses were not tested. Effects on adrenals, kidneys, thyroid and
spleen, as well as effects on spermatogenesis, have been reported with administra-
tion of somewhat higher dose levels of NaCN in food.
Conclusions
The critical effect of occupational exposure to cyanide is its effect on the central
nervous system. Severe CNS effects have been reported after occupational
exposure to air concentrations of 4 to 12 ppm cyanide (breathing zone). Some
effects on thyroid have also been documented at these air concentrations. Similar
toxic effects on the CNS and thyroid have also been reported in laboratory
animals exposed to HCN, NaCN or KCN. Pharmacological studies indicate that at
exposures to air concentrations around 3 ppm cyanide can accumulate in the
body. Cyanide is rapidly absorbed through the skin and can cause acute and
sometimes lethal poisoning.
Table 1. Dose-effect relationships reported in humans exposed to cyanide by inhalation.
Exposure Effect Ref.
270 ppm Lethal (death within 6 to 8 minutes) 25
181 ppm Lethal (death after 10 minutes) 30
135 ppm Lethal (death after 30 minutes) 30
110-135 ppm Highly dangerous/lethal (death within 30 to 60 minutes) 25
4.2-12.4 ppm*
(average 6.4-10.4 ppm)
Headache, weakness, changes in sense of taste and
smell, dizziness, throat irritation, vomiting, shortness
of breath with exertion, watery eyes, chest pains,
psychoses, slight to moderate thyroid enlargement,
changes in blood parameters (including higher
hemoglobin levels and lymphocyte counts)
22
* Occupational exposure (plating bath containing 3% NaCN and 3% copper cyanide)
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Table 2. Exposure-effect relationships observed in laboratory animals exposed to HCN
by inhalation.
Exposure Species Effects Ref.
100 ppm,
19 minutes
Monkey Hyperventilation, irregular heartbeat, ataxia,
other effects
67
63 ppm
30 minutes
Mouse DC50, intermittent sensory irritation 58
60 ppm
30 minutes
Monkey Somewhat elevated respiratory minute volume,
changes in EEG, reduced amplitude of auditory
cortical evoked potential toward end of
exposure period
66
55 ppm
30 minutes
Rat Increased transthoracic pressure, air flow and
tidal volume; reduced compliance, respiratory
rate and minute volume, reduced content of
phospholipids in lungs
9
45 ppm
30 minutes/day
28-96 days
Dog Breathing difficulty, vomiting, diarrhea, tremor,
spasms, effects on locomotion, coma, death,
histological changes in brain
4
45 ppm
30 minutes
Mouse Animals remain lying on their sides 25
45 ppm
25 minutes
Cat Animals remain lying on their sides 25
45 ppm
15 minutes
Dog Animals remain lying on their sides 25
0.5 ppm
24 hours/day
4 weeks
Rabbit No exposure-related effects on heart or lungs 42, 43
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Table 3. Exposure-effect relationships observed in laboratory animals with repeated oral
or subcutaneous administration of NaCN or KCN.
Exposure Dose as CN
mg/kg bw/day
Species Effect Ref.
NaCN, gavage
2 mg/kg bw/day,
14.5 months
1.1 Dog Occasional convulsions, apnea,
vomiting in conjunction with
administration; inflammatory
changes in digestive tract,
degenerative changes in CNS,
changes in blood profile
36
NaCN, in diet
(=10.8 mg HCN/kg
feed)
14 weeks
1.04 Dog Nephrosis, hyperplasia and
hypertrophy of adrenals, effects on
spermatogenesis
47
NaCN, in diet
(=10.8 mg HCN/kg
feed)
14 weeks
1.04 Dog Lowered T4 in serum, somewhat
higher thyroid weight, hyperplasia
of thyroid, necrosis, fibrosis and
atrophy of spleen, lower weight
gain
48, 49
KCN, s.c. injection
1.4 mg/kg bw
once a week
22 weeks
0.57* Rat Degenerative changes in CNS,
lower vitamin B12 levels in liver
24, 77
NaCN, in drinking
water
10 mg/liter
0.9-1 mg/kg bw/day
13 weeks
0.5 Rat Somewhat lower weight gain
(males)
34
KCN, gavage
1 mg/kg bw/day
24 weeks
0.4 Pig Reduced T3 and T4 in blood,
increase in blood glucose, effects
on behavior
45
NaCN, gavage
0.5 mg/kg bw/day
13.5 months
0.27 Dog Symptoms of acute poisoning after
53 weeks; inflammatory changes in
digestive tract, slight degenerative
changes in CNS, changes in blood
profile
36
NaCN, in drinking
water
3 mg/liter
0.3 mg/kg bw/day
13 weeks
0.16 Rat No notable effects 34
*mg/kg bw/injection
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Consensus Report for Toluene
Diisocyanate (TDI), Diphenylmethane
Diisocyanate (MDI), Hexamethylene
Diisocyanate (HDI)
May 30, 2001
There are a large number of isocyanates, and the present document covers three of
the most common ones: toluene diisocyanate (TDI), diphenylmethane-4,4´-
diisocyanate (MDI), and hexamethylene diisocyanate (HDI). It also serves as an
update to the Consensus Reports published in 1982 and 1988 (130, 74). Thermal
breakdown products of polyurethane are not discussed.
Chemical and physical characteristics. Uses
toluene-2,4-diisocyanate (2,4-TDI)
CAS No.: 584-84-9
Synonyms: 2,4-toluene diisocyanate
2,4-diisocyanatotoluene
4-methyl-1,3-phenylene diisocyanate
toluene diisocyanate
Structure:
CH3
NCO
NCO
Melting point: 21 °C
Flash point: 135 °C
toluene-2,6-diisocyanate (2,6-TDI)
CAS No.: 91-08-7
Synonyms: 2,6-toluene diisocyanate
2,6-diisocyanatotoluene
2-methyl-1,3-phenylene diisocyanate
toluene diisocyanate
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Structure:
CH3
NCOOCN
2,4-TDI:2,6-TDI (4:1)
CAS No.: 26471-62-5
Melting point: 12.5-13.5 °C
Flash point: 132 °C
For all of the above:
Formula: C9H6N2O2
Molecular weight: 174.16
Density (liquid): 1.22 g/cm3 (25 °C)
Density (vapor): 6.0 (air = 1)
Boiling point: 251 °C
Vapor pressure: 2.7 Pa (25 °C)
Saturation concentration: 27 ppm
Conversion factors: 1 µg/m3 = 0.138 ppb
1 ppb = 7.239 µg/m3
diphenylmethane-4,4´-diisocyanate (MDI)
CAS No.: 101-68-8
Synonyms: methylenebis(phenylisocyanate)
4,4´-diphenyl methane diisocyanate
bis(1,4-isocyanatophenyl)methane
4,4´-methylenediphenyl diisocyanate
4,4´-diisocyanato-diphenyl methane
diphenylmethane diisocyanate
4,4´-methylphenyl diisocyanate
Formula: C15H10N2O2
Structure:
CH2OCN NCO
Molecular weight: 250.3
Density (liquid): 1.23 g/cm3 (25 °C)
Density (vapor): 8.5 (air = 1)
Boiling point: 314 °C
Melting point: 39.5 °C
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Flash point: 196 °C
Vapor pressure: 6.7 x 10-4 Pa (25 °C)
Saturation concentration: 6.6 ppb
Conversion factors: 1 µg/m3 = 0.096 ppb
1 ppb = 10.40 µg/m3
hexamethylene-1,6-diisocyanate (HDI)
CAS No.: 822-06-0
Synonyms: 1,6-diisocyanatohexane
1,6-hexamethylene diisocyanate
Formula: C8H12N2O2
Structure: OCN–(CH2)6–NCO
Molecular weight: 168
Density (liquid): 1.04 g/cm3
Boiling point: 212.8 °C
Melting point: - 67 °C
Flash point: 140 °C
Vapor pressure: 1.3 Pa (20 °C)
Saturation concentration: 13 ppm
Conversion factors: 1 µg/m3 = 0.143 ppb
1 ppb = 6.991 µg/m3
Isocyanates are characterized by their reactive -N=C=O group. Some diiso-
cyanates (TDI, HDI) are volatile at room temperature and others can not be
inhaled unless they are heated or in aerosol form (MDI). MDI and TDI usually
occur industrially as mixtures of different isomers and/or in prepolymerized form.
Industrial grade TDI is usually a mixture of 2,4-TDI and 2,6-TDI in a ratio of 4:1
or 65:35. MDI usually occurs as a mixture of several isomers and oligomers: one
common mixture is approximately 30-40% diphenylmethane-4,4´-diisocyanate,
2.5-4.0% diphenylmethane-2,4´-diisocyanate, 0.1-0.2 % diphenylmethane-2,2´-
diisocyanate, and the remaining 50-60% oligomers. HDI rarely occurs in mono-
meric form and is usually in adducts.
Isocyanates are used in the production of polyurethane, a common material for
soft and hard foam plastics, insulation materials, two-component adhesives, foam
rubber, and various types of paints and hardeners. TDI is used primarily in the
production of low-viscosity polyurethane foam, and MDI is used for the produc-
tion of harder polyurethane items (in catalyzers, for example). TDI and MDI are
used in surface coatings (e.g. for chutes used in mining and agriculture), in the
shoe industry for shoe soles, in the automobile industry for shock absorbers, and
in a wide variety of other industries. MDI occurs in foundries in binders for
casting forms, and in orthopedic surgery in casts for broken bones.
The reported odor threshold for TDI is 360-920 µg/m3 (53). MDI is reported to
be odorless (52). There is no information regarding the odor theshold for HDI.
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Measuring air concentrations of TDI, MDI and HDI
Measuring isocyanates in air is complicated by several factors (97, 129).
Isocyanates are extremely reactive compounds. They may occur as gases or as
particles of various sizes in aerosols. The monitoring method must be specific and
extremely sensitive, since the threshold values are low. Because of the high
reactivity of isocyanates, samples must be taken using chemosorption, i.e. by
derivitization using a reagent in solution or a reagent-impregnated solid medium,
and this must be followed by chromatographic analysis. The method in general
use before the introduction of chromatography was the spectrophotometric
Marcali method (86). Measurements made with the Marcali method must be
regarded with considerable reservation today, since the sensitivity and specificity
of the method do not meet present standards. In simple exposure situations,
however, the Marcali method may yield reliable values for TDI.
The reagents most widely used during the past 20 years for isocyanate
derivatization in conjunction with chromatographic analysis are the following:
N-[(4-nitrophenyl)methyl]propylamine (‘NITRO reagent’)
9-(N-methylamino methyl)-anthracene (MAMA)
1-(2-pyridyl)-piperazine (PP)
1-(2-methoxyphenyl)-piperazine (MP)
1-(9-anthracenylmethyl)-piperazine (MAP)
tryptamine (TRYP)
di-n-butylamine (DBA)
In monitoring TDI, MDI and HDI, the most important parameters are the
gas:particle ratio and the size and reactivity of any isocyanate particles that may
be present. It is probable that under certain conditions (such as spraying of quick-
setting MDI products) the particles react too slowly with the reagent when
samples are taken on reagent-impregnated filters, and samples must therefore be
taken in an impinger (4). On the other hand, particles smaller than 2 µm are not
captured effectively in an impinger. It is therefore recommended that, in environ-
ments containing both quick-drying particles larger than 2 µm and particles
smaller than 2 µm, sampling in an impinger be followed by sampling on a
reagent-coated fiberglass filter (47, 128). In one of the methods commonly used in
other countries, samples are taken in an impinger containing MP in toluene or on a
fiberglass filter coated with MP (47). MAMA in toluene has been widely used in
Sweden (11). For monitoring monomeric TDI, MDI and HDI in environments
where these substances are generated by polyurethane production, the choice of
reagent is generally not of critical importance. DBA in toluene has several
advantages over other reagents (135), but disadvantages have also been found
(67). As a rule, reagent-coated filters should be extracted in the field right after
the sample is taken. With regard to measuring TDI, MDI and HDI in complex
environments – around thermal breakdown of polyurethane materials, for example
– our knowledge of the efficiency of the various reagents and sampling methods is
still quite limited.
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Liquid chromatography is the only method used to separate isocyanates prior
to analysis. One or a combination of detectors – UV, fluorescence, electro-
chemical – may be used for identification and quantification (97, 129). To
identify and quantify samples from complex environments it is necessary to
use mass spectrometry. DBA is the reagent that has been most thoroughly
investigated in conjunction with mass spectrometric analysis (54, 57, 136).
International standards are being drawn up for methods based on MP, MAP,
DBA, various combinations of reagents, and different sampling methods (54).
In summary, we now know that earlier measurements of isocyanates, partic-
ularly in complex environments (with thermal breakdown, for example), can be
off by a wide margin – especially if they were made before the introduction of
chromatography. Further, sampling in an impinger may yield measurements that
are too low because the particles smaller than 2 µm were not captured. Chromato-
graphic analysis of derivatized isocyanates without confirmation by mass spectro-
metry may lead to concentration estimates that are too high. When the derivatiza-
tion reaction is slow, competing reactions may lead to estimates that are too low.
In assessing the results of epidemiological studies, therefore, the monitoring
method must always be assessed as well. If a study is to be accepted as reliable,
the exposure levels must be determined by modern chromatographic methods. An
exception may be made for measurements made in simple exposure situations,
where determination with the Marcali method may be acceptable.
Uptake, biotransformation, excretion
In studies with rats and guinea pigs it has been shown that inhaled TDI is
absorbed in the central respiratory passages and far out in the bronchioles (61).
In general, isocyanates bind to proteins quite rapidly (62). Skin uptake of TDI
has been demonstrated in rats after exposure 3 hours/day for 4 consecutive days
(115).
Due to their –N=C=O group, isocyanates are extremely reactive substances that
form adducts. Urine samples taken after exposure to isocyanates contain the
corresponding amines, which can be identified if the sample is prepared by
hydrolysis. Thus, toluene diamines (TDA) can be found after exposure to TDI
(115), 4,4´-methylenedianiline (MDA) and N-acetyl-4,4´-methylenedianiline
(AcMDA) after exposure to MDI (124), and 1,6-hexamethylene diamine (HDA)
after exposure to HDI (15). It has been assumed on the evidence of in vitro studies
that the toxicity of isocyanates is largely due to the distribution of isocyanate-
glutathione conjugates to various organs via blood and the release of free
isocyanate in peripheral tissues. This occurs particularly with low local concen-
trations of glutathione (GSH) or elevated pH (14, 102). The distribution of
isocyanates in the human body, however, is largely unknown.
Data on metabolism of isocyanates are also sparse. In experiments in which rats
were given 14C-TDI in diet, insoluble polymers were formed in the stomach at
high doses (900 mg/kg b.w./day) in feed, but not at lower doses (60 mg/kg
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b.w./day) (53). The metabolites of 2,6-TDI are excreted primarily in feces. Oral
administration of 2,6-TDI in oil (900 mg/kg b.w.) resulted in formation of
polymers in the digestive tract, and 2,6-TDI polymers were still in the digestive
tract 72 hours later. The half time for 2,6-TDI in aqueous solution is less than 2
minutes in the ventricle and less than 30 seconds in serum (53). MDI and TDI
have been found in and below the respiratory epithelium of exposed laboratory
animals from the nose to the terminal bronchioles. TDI-protein complexes have
been found in pulmonary tissue of guinea pigs after inhalation of TDI (60).
Bronchoalveolar lavage fluid from TDI-exposed guinea pigs contained five TDI-
protein complexes, of which TDI-albumin was the most prevalent (56). In humans
exposed to airborne 2,4-TDI and 2,6-TDI, the substances are bound mostly to
albumin in plasma (70). TDI-hemoglobin complexes have been identified in
guinea pigs after inhalation of TDI (27). After rats had been exposed by inhalation
to 14C-TDI, the highest concentrations of radioactivity were found in respiratory
passages, digestive tract and blood, in that order. The radioactivity in plasma was
linearly related to the dose of inhaled 14C-TDI, and the 14C-labeled compounds
were almost entirely in the form of conjugates (63).
Biological measures of exposure
Volunteers exposed to HDI in a test chamber (3.6 ppb for 7.5 hours) had the
corresponding amine (1,6-hexamethylene diamine, HDA) in hydrolyzed urine
(15). The biological half time was about 1 hour. In a similar study with lower
exposures (1.7 to 3.1 ppb for 2 hours), HDA levels in urine were proportional to
HDI levels in air, and the half time was 2.5 hours (134). HDA could not be found
in unhydrolyzed urine, which suggests that this metabolite occurs as an adduct.
HDA was not detected in plasma in either of these studies (15, 134). HDA could
be identified in hydrolyzed urine from car painters exposed to prepolymerized
HDI (116) and production workers making HDI monomers (80). Of 22 car
painters who used HDI-based paint and wore face masks with air filters, 4 had
HDA in hydrolyzed urine; none of seven controls had detectable amounts (149).
Subjects exposed to 2,4-TDI and 2,6-TDI in a test chamber (5.5 ppb for 7.5
hours) had the corresponding amines in plasma and urine – identified by gas
chromatography-mass spectrometry (GC-MS) after hydrolysis (125). Elimination
from plasma was slow. Elimination in urine had a slow and a fast phase, the latter
with a biological half time of one to two hours. Two persons were exposed to
three concentrations in the range 3.4-9.7 ppb for 4 hours, and there was a
correlation between TDI levels in air and TDA levels in plasma (16). Elimination
from plasma had two phases. The biological half time was two to five hours for
the fast phase and more than six days for the slow phase (16).
In a cross-sectional study of employees making automobile upholstery in a
workplace where there was low exposure to both aerosols from spraying of MDI
and HDI adhesives and thermal breakdown products from the adhesives and from
TDI foam (air concentrations of MDI <0.76 ppb, HDI <0.1 ppb, TDI <0.01 ppb),
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toluene-2,4-diamine (2,4-TDA) and toluene-2,6-diamine (2,6-TDA) were detected
in hydrolyzed plasma from respectively 16% and 7% of the production workers,
but none of the office workers (72). Some TDA isomer was found in the urine of
48% of the production workers and 21% of the office workers.
A TDI metabolite (2,6-TDA), but not TDI, could be identified in hydrolyzed
urine from workers exposed to 2,6-TDI (79, 117). There was some correlation to
air concentrations. Workers exposed to TDI (≤ 0.5 ppb) in a foam plastic factory
were monitored for 5 weeks: the urine content of TDA fluctuated, as did the ratio
between 2,4-TDA and 2,6-TDA (103). There was some correlation with air
concentrations. The amounts of TDA in plasma were relatively constant, and not
correlated to amounts in urine. In another study of workers in two foam plastic
factories where air concentrations of TDI were 0.05-0.5 ppb and 1.4-16.6 ppb
respectively, the TDA levels in plasma reflected the difference in air concen-
trations (69). While the workers were on vacation the levels in plasma declined
with an average half time of 21 days. The levels of TDA in urine dropped also,
with a half time of 5.8 to 11 days and some indication of two phases.
Workers exposed to TDI (average 4.1 ppb) in a foam plastic factory had TDA
in hydrolyzed plasma and urine (135). TDA in plasma of some of the workers
experimentally exposed for a short time had a biological half time of about 10
days. The amount of TDA in urine from the workers varied quite a bit, and was
highest right after work. There was no clear correlation between TDI levels in air
and TDA levels in plasma or urine. The levels in plasma and urine were higher
and the half time in plasma longer than they were for the briefly exposed subjects
in the test chamber studies (16), which lends support to the hypothesis that there
is a slow compartment. In plasma from a worker in the same factory, most of the
metabolite was covalently bound to albumin (70).
Methylenedianiline (MDA) could be identified in pooled samples of
hydrolyzed plasma and urine from 10 workers exposed to MDI (it is unclear
whether thermal breakdown was involved) (126). MDA could be identified in
hydrolyzed hemoglobin from 10 of 26 workers exposed to MDI (all but three <0.3
ppb; values for the other three were 1.0, 1.8 and 2.9 ppb) (122). After alkaline
extraction there were measurable amounts of acetyl-MDA (AcMDA) and lesser
amounts of MDA in urine from 18 of the 26, MDA alone in 4 samples, and
neither substance in 4. After acid hydrolysis the MDA levels were on average
about 1/3 higher that the total of AcMDA and MDA in the previous analysis. The
levels of hemoglobin adducts had no correlation to metabolites in urine (122).
In a polyurethane production facility where air concentrations of MDI were
usually below the detection limit, measurable amounts of 4,4´-MDA (0.035-0.83
pmol/ml) and AcMDA (0.13-7.61 pmol/ml) could be found in urine in 15 of 20
workers after alkaline extraction, and MDA values were 6.5 times higher after
acid hydrolysis. MDA was found as hemoglobin adducts in all the examined
workers, and one worker also had adducts of AcMDA. Plasma levels of
4,4´-MDA ranged from 0.25 to 5.4 pmol/ml, up to 120 fmol/mg of which was
covalently bound to albumin (124).
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2,4-TDA, 2,6-TDA and 4,4´-MDA could be found in hydrolyzed urine from 15
workers at a workplace where TDI- and MDI-based polyurethane was heated
(26). The levels fluctuated widely from day to day. Levels of these metabolites in
plasma were much more stable. In four of the monitored workers the levels of
MDA declined during an exposure-free period, with biological half times of 2.5-
3.4 days in urine and 10-22 days in plasma.
It has long been known that some persons exposed to isocyanates form anti-
bodies specific to conjugates of the isocyanate and serum albumin (40, 147).
These are of doubtful pathogenic relevance, but may be used as biomarkers of
exposure (for those persons who develop antibodies). Three percent of workers
exposed to spray aerosols of glue based on MDI or HDI had specific IgE
antibodies, while 33% had IgG specific to MDI, 32% to TDI and 12% to HDI
(72).
After exposure stops, the titer of specific antibodies declines (22, 81), but it
may remain elevated for as long as five years (71).
To sum up, it seems that in principle conditions exist for biological monitoring
of exposure to isocyanates. With regard to biomarkers for exposure, it is possible
to analyze metabolites in plasma and urine, although it involves considerable
work with sample treatment, determination by chromatography- mass spectro-
metry, and quality control. Levels of metabolites in urine samples taken soon after
an exposure following a period without exposure reflect the exposure of the
previous hours, whereas levels in plasma reflect more long-term exposure.
However, there is much that is not known – both generally and about the
individual monomers. In all cases the relative importance of gas and particles in
exposures is far from clear. The relevance of skin uptake is still largely unstudied.
A special problem with biomonitoring is the difficulty of differentiating exposure
to a diisocyanate from exposure to its amines and aminoisocyanates. For HDI the
analytical problems are such that only high exposures can be detected.
Specific IgG in serum increases with exposure to HDI, TDI and MDI, but in
only some exposed persons. The temporal relationship to exposure is not clear.
The concentrations persist for months and even years after exposure has stopped.
Virtually nothing is known about quantitative relationships between air concentra-
tions and specific IgG. Similarly, very little is known about the relation between
antibody concentration and risk of health problems. The only existing data pertain
to respiratory symptoms and exposure to HDI, TDI and MDI in environments
with thermal breakdown. Specific IgE is probably of very limited value for
estimating exposure and risk.
Toxic effects
Animal data
For rats, the calculated LD50 for a single oral dose of TDI is 5.8 g/kg (152). The
LC50 for exposure via inhaled air, 4 hours/day for 2 weeks, was 9.7 ppm for
mice, 12.4 ppm for guinea pigs, and 13.8 ppm for rats. Watery eyes, salivation,
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agitation and hyperactivity were noted in the animals during the exposures (31).
Inhalation of up to 18 ppb 2,4-TDI for 3 hours caused no change in the respiratory
rate of mice, either after a single exposure or after the exposure was repeated for
several days. Inhalation of 23 ppb for 3 hours did reduce the respiratory rate,
however, and the effect was enhanced when the exposure was repeated the
following day (120). Acute inhalation exposure to high concentrations of TDI
causes extensive damage and necrosis in pulmonary epithelium, and leads to
death of the animals by occlusion of bronchioles with necrotic tissue, edema in
mucous membranes, and the severe inflammatory reaction (31). Mice that inhaled
TDI (time-weighted average 400 ppb) 6 hours/day for 5 days had squamous
metaplasias, exfoliative changes, erosion and ulceration in nasal epithelium (18).
Exposure to 98 ppb TDI 6 hours/day for 4 days caused inflammation and necrosis
in respiratory epithelium of mice (51). MDI and TDI present about the same toxic
picture in experimental animals. In an inhalation toxicity study (113), the acute (4
hours) LC50 for rats exposed to an aerosol mixture of respirable MDI monomers
and polymers (with ≤ 0.005% w/w phenyl isocyanate) was 490 mg/m3 (95%
confidence interval 376-638 mg/m3). Two weeks of exposure to a mixture of
MDI polymers with 44.8-50.2% monomer at a concentration of 13.6 mg/m3
resulted in severely retarded growth and some deaths, and 13 weeks of exposure
to 12.3 mg/m3 also caused elevated mortality and retarded growth (113).
For mice, inhalation of 50 or 150 ppb TDI (2,4-TDI:2,6-TDI, 4:1) 6 hours/day
for 104 weeks resulted in significantly lower body weights in the high-dose group
and elevated mortality among females in both exposure groups (survival in
controls 40%, low-dose group 23%, high-dose group 26%). No such increase in
mortality was seen for the males (49). Interstitial pneumonitis and necrotic
changes in nasal mucosa were observed at both exposure levels (49). Rats were
exposed to 50 or 150 ppb airborne TDI 6 hours/day, 5 days/week for 108 weeks
(females) or 110 weeks (males): they initially lost weight, but weight
development was normal after 12 weeks of exposure. There were no effects on
survival and no observed changes in mucous membranes in the upper respiratory
passages (49).
In rabbits and guinea pigs, toluene diisocyanate induces bronchial hyper-
reactivity to acetylcholine, with a dose-response relationship (37, 38, 89, 120).
Increased bronchial response to acetylcholine was observed in guinea pigs after
4 x 1 hours of exposure to TDI (unspecified isomer) in concentrations of 10 or
30 ppb, but not 5 ppb (90). In some experiments the animals were pre-treated with
capsaicin, and it was found that this counteracted the isocyanate-induced increase
in bronchial reactivity. This probably indicates that neuropeptides are involved in
the pathophysiological sequence (90, 109). Guinea pigs developed respiratory
tract hypersensitivity to TDI after dermal exposure (59).
Wistar rats were exposed to an MDI aerosol (a mixture of polymers with 44.8-
50.2% monomer) 6 hours/day, 5 days/week for up to two years: exposure to
576 ppb resulted in hyperplasia of basal cells in olfactory epithelium and
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accumulation of alveolar macrophages with surrounding fibroses in the lungs
(112).
Bronchial reactivity in guinea pigs was increased more by dermal application of
MDI (intradermal 0.0003-0.3%; epidermal 10-100%) than by inhalation exposure
(2775 or 3390 ppb) (110). Bronchoalveolar lavage fluid from guinea pigs with
TDI-induced bronchial hyperreactivity contained elevated numbers of eosino-
philic granular leukocytes (eosinophils) and elevated concentrations of cysteinyl
leukotrienes, leukotriene B4 (LTB4) and prostaglandin F2_ (PGF2_) (111).
Several polyisocyanate prepolymers were assessed for their potential to induce
contact allergy (delayed dermal hypersensitivity) in a study with guinea pigs,
using the method described by Buehler (154). TDI and HDI were among the
substances tested, and both were strongly allergenic. Eighteen of 20 animals were
sensitized to TDI, which was ranked as a grade V allergen on the Magnusson-
Kligman scale (78); the induction concentration was 5% and the test concentra-
tion was 1%. Fourteen of 20 animals were sensitized to HDI, which was ranked as
a grade IV allergen on the Magnusson-Kligman scale (78); the induction
concentration was 1% and the test concentration was 0.1%. The control animals
tested negative. Isocyanates have also been tested on mice for skin sensitization,
measured as ear swelling. TDI (131, 133, 137), MDI (131, 133) and HDI (133)
were found to be contact allergens. HDI was observed to be more potent than
MDI, which in turn was more potent than TDI (133). The SD50 (the dose that
sensitized 50% of animals) was 0.088 mg/kg for HDI, 0.73 mg/kg for MDI and
5.3 mg/kg for TDI. It was also demonstrated in this study that the different
isocyanates cross-reacted and that TDI, which was the least potent sensitizing
agent, also had the lowest tendency to cross-react (133). A 5% (but not 1%)
solution of TDI (2,4-TDI:2,6-TDI, 4:1) caused ear swelling in previously
unexposed mice. After sensitization, the 1% solution also caused ear swelling
(131). Sensitization was observed in 7 of 8 guinea pigs seven days after dermal
application of TDI (2,4-TDI:2,6-TDI, 4:1) (59). A number of other studies with
guinea pigs, which were made by methods other than those prescribed in the
OECD Guideline (99), have also shown that MDI and TDI are medium-strong to
strong contact allergens (59, 66, 110).
Human data
Irritation of respiratory passages
Vid TDI-koncentrationer (exponeringen vanligtvis ej närmare karakteriserad men
Seven men exposed to TDI (the substance is usually not more closely specified in
these studies, but in most cases is probably a 4:1 mixture of 2,4-TDI and 2,6-TDI)
concentrations exceeding 100 ppb (724 _g/m3) immediately showed symptoms
of respiratory irritation (cough, nasal congestion, throat irritation) (91). It has long
been known that exposure to TDI in concentrations exceeding 500 ppb results in
irritation of the nose and throat (152). In a study of 379 TDI-exposed workers at
14 workplaces, 30% (n = 115) had symptoms that could with some confidence be
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attributed to their exposure (32). All 12 persons exposed to (unspecified) iso-
cyanates in the concentration range 30-70 ppb had symptoms in the form of
cough, dyspnea and/or irritation of mucous membranes in nose and throat (43).
In this study, at exposures below 30 ppb no immediate symptoms of respiratory
irritation were seen in persons who were not hypersensitive to isocyanate (43). A
WHO report published in 1987 states that exposure to TDI concentrations
exceeding 50 ppb causes irritation of eyes and upper and lower respiratory
passages (53). This report does not mention the source of the original data. The
exposure measurements in most of the studies reviewed here were made by
methods that do not meet present standards.
Exposure to MDI is irritating to skin, eyes and respiratory passages (52). For
MDI, the relationship between symptoms and exposure levels is still insufficiently
known. In one study, nose and throat irritation was observed in about half of 13
employees who had been transferred because of their reactions to isocyanate
exposure and in a few of the 20 who had stayed in the same jobs and were still
being exposed. Precise exposure levels are not given in this study, but it is
reported that the exposure limit for MDI (96 ppb) was reached during some
operations and that higher peaks may have occurred (65).
Asthma and asthma-like symptoms
People who become hypersensitive to isocyanates develop symptoms such as
coughing, rales and dyspnea at exposures below 20 ppb (10, 13, 98, 151).
Isocyanate-induced asthma often begins with coughing and breathing difficulty in
conjunction with exposure, but sometimes bronchial obstruction with exertion or
on exposure to other bronchoconstricting stimuli is the only symptom of incipient
isocyanate asthma. The asthmatic reaction may be of either the immediate (within
30 minutes of exposure) or delayed type (3 to 6 hours after exposure), and may
also be biphasic. Persons with isocyanate asthma sometimes have rhinitis and/or
conjunctivitis, and may have urticarial reactions as well (8).
In a prospective cohort study, 89 previously unexposed workers who were
employed in the manufacture of TDI were followed for 2.5 years (20). TDI levels
registered by stationary monitors (8-hour time-weighted averages, 10 occasions)
were in the range 3-54 ppb, median 6.5 ppb; personal monitors showed 1-25 ppb,
median 5 ppb. The TDI-exposed workers had a significantly higher occurrence of
symptoms involving the lower respiratory passages (cough, wheezing, chest tight-
ness, dyspnea etc.) than unexposed controls (20).
A review article by Musk et al. addresses the problems of defining a
relationship between isocyanate exposure and effects on health and determining
the relative importance of brief exposures to high concentrations and continuous
exposure to low concentrations (96). It has been proposed that, for healthy
persons, brief episodes of high exposure are more likely to lead to isocyanate
asthma than long-term exposure to lower concentrations. The relative importance
of high, short-term exposures and low, long-term exposures in the development of
isocyanate asthma is still unclear, however.
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White et al. (148) examined 203 women who were occupationally exposed to
TDI while sewing automobile seat covers of polyurethane plastic. In some parts
of the factory there was exposure to both TDI and fibrous dust. In an initial sub-
study of 68 women who worked in the factory, 48 of whom worked with the
polyurethane material, 17 (25%) were found to have respiratory symptoms. Ten of
these had developed symptoms and three had become worse after they began
work (and thus exposure) at the factory. It is not clear from the report how many
of the 48 upholstery workers reported periods of breathing difficulty and
wheezing on the questionnaire the subjects filled in for a medical interview.
Another sub-study reports periods of dyspnea and wheezing in 30% of the
women: 24% worked with the upholstery material and 11% had other jobs where
they were not exposed to TDI. The difference between these groups was not
statistically significant, however. Furthermore, the group exposed to isocyanates
contained more smokers (55%; 42% in controls), and there was no attempt to
adjust for this difference. The levels of TDI were monitored in the breathing zone
of the women while they were working, and also near the needles of the sewing
machines and the scissors used to cut the plastic. Air samples were collected for
5 to 29 minutes (= 5 to 29 liters of air) and analyzed with HPLC. One short-
coming of this study is that it is not clear how many measurements were used to
calculate the exposure levels. The measured air concentrations of TDI were
between 0.3 and 3 ppb, and in the opinion of the authors there were no exposure
peaks that deviated significantly from these values. Dust concentrations reportedly
did not exceed 1 mg/l (1000 mg/m3) (148). The most serious shortcomings of this
study are inadequately reported exposure data and flawed data analysis.
In an English study (93), exposure conditions for 27 workers whose isocyanate
asthma had been reported to a register were compared with conditions for 51
persons in the same factory who did not have asthma. Individual exposures to TDI
were measured with the paper tape method (described in Reference 29) during the
entire workshift, and reported as 8-hour time-weighted averages (TWA) and
exposure peaks. The 8-hour TWA was somewhat higher for the asthma cases
(1.5 ppb; 95% confidence interval 1.2-1.8 ppb) than for controls (1.2 ppb; 95%
confidence interval 1.0-1.4 ppb). Individual top exposures were between 1 and
50 ppb, the same for cases and controls. For persons whose exposure was higher
than the median value for the control group (1.125 ppb), the odds ratio for
developing asthma was 3.2 (95% confidence interval 0.96-10.6). An exposure
increase of 0.1 ppb corresponded to an 8% increase in risk of developing asthma.
Time from hiring to the onset of asthma symptoms ranged from less than 1 month
to 23 years (median 21 months). The authors describe the study as a case-referent
study, but it is a dubious description since the cases are defined by both their
illness and their exposure. Exposure conditions for the asthma cases and for
controls were estimated later by monitoring workers doing similar jobs. A
prerequisite for the study to be valid is that workers with low and high exposure
within in the same area had the same chance to be diagnosed as having asthma.
The authors do not make clear whether this requirement was met. The study, for
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this reason and others, provides no solid basis for any conclusions on dose-
response or dose-effect relationships.
In the cohort study reviewed above (20), a few of the workers hypersensitive to
TDI developed severe bronchial obstruction after bronchial provocation with
5 ppb TDI. Bronchial provocation with different concentrations of isocyanates
elicited asthma-like reactions in workers who had previously experienced
coughing and chest tightness in conjunction with exposure to isocyanates (6), see
Table 1. In brief, concentrations of ≤ 20 ppb triggered asthma symptoms in 16 of
59 workers exposed to MDI, 12 of 40 exposed to TDI and 3 of 42 exposed to HDI
(6). Bronchial obstruction was observed in four workers hypersensitive to
isocyanates at TDI exposures estimated by the authors of one study to be about
1 ppb, though it is not clear how this exposure level was determined (24). In
another study, specific bronchoprovocation tests were given to persons with
suspected occupational asthma and exposure to TDI, MDI or HDI at work
(average exposure time 8.8 years). They were exposed in a test chamber to the
individual isocyanates in concentrations of 5 to 20 ppb for up to 2 hours. Four of
six subjects had positive reactions to TDI, 10 of 17 to MDI, and 15 of 39 to HDI
(25). For persons who have developed TDI asthma, it seems to be the cumulative
dose that determines whether symptoms appear. In a study by Vandenplas et al.
4 persons with isocyanate asthma were each exposed to TDI on 3 or 4 occasions.
The total dose on each occasion was equivalent to the dose that had previously
been shown to cause a 20% reduction of FEV1 for that subject, but the concentra-
tion ranged from 5 to 20 ppb and the exposure time ranged from 1 to 90 minutes.
It was found in this study that exposure to low concentrations of TDI for longer
periods triggered the same reaction as exposure to higher concentrations for
shorter periods, provided that the total dose was the same (140).
Table 1. Results of experimental provocation exposure of 141 workers who were
occupationally exposed to isocyanates and had work-related dyspnea. Subjects were
exposed to 5 ppb for 15 minutes, followed by 10 ppb for 30 minutes, followed by 20 ppb
for 5 minutes. The table shows, for each tested diisocyanate, the number of persons
having asthma-like reactions at each concentration (6).
5 ppb 10 ppb 20 ppb
MDI (n=59) 6 2 8
TDI (n=40) 1 3 8
HDI (n=42) 0 2 1
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Six cases of occupational asthma were identified in a group of 48 spray painters
who were exposed to TDI, MDI and HDI at work. Exposure levels were not
determined in this study (123). Foundry workers who had developed asthma with
hypersensitivity to isocyanates had positive reactions to one hour of exposure to
MDI (bronchial provocation in a test chamber). The exposure levels in this study
were on average 12 ppb and never higher than 20 ppb (151).
Bronchial inflammation due to isocyanate asthma, regardless of which
isocyanate is the cause, resembles that observed with other types of asthma.
Bronchial biopsies from patients with isocyanate asthma have elevated levels of
activated eosinophils in mucosa and submucosa and higher numbers of mast cells
in epithelium (35). Bronchoalveolar lavage fluid and biopsies of respiratory
mucosa from persons with isocyanate asthma contain elevated numbers of
eosinophils and activated lymphocytes (83, 84, 119). Induced sputum from
patients with isocyanate asthma contains elevated numbers of eosinophils (76).
Indications of eosinophil activation (eosinophil cationic protein (ECP)) in blood
increase after provocation with isocyanate (85). In patients with isocyanate
asthma, acute exposure to TDI (unspecified isomer) leads to a temporary increase
in the number of lymphocytes containing interleukin 4 in respiratory mucosa,
possibly indicating a preponderance of Th2 lymphocytes (77). Early in the
reaction to TDI there is a migration of neutrophilic granular leukocytes (neutro-
phils) to the respiratory passages. This has been observed with TDI provocation in
persons occupationally exposed to TDI (34) and also in animal studies (46, 111).
It resembles the early phase of the allergic asthma reaction, when an invasion of
neutrophils can be observed in airways (28, 30, 94). Asthmatics with delayed
reactions triggered by TDI (unspecified isomer) also have elevated numbers of
eosinophils and CD8-positive lymphocytes in blood (36). Stimulating mono-
nuclear blood cells with antigens to TDI-, MDI- and HDI-albumin complexes
liberates more histamine releasing factors in patients with isocyanate asthma than
in asymptomatic controls exposed to diisocyanate (45, 73). The authors suggest
that liberation of histamine releasing factors on specific provocation might serve
as a biological marker for isocyanate asthma.
Some studies report a correlation between certain HLA types and risk of
developing TDI-induced asthma. There was an elevated risk of developing asthma
as a result of TDI exposure for persons who had the allele DQB1*0503 or the
allele combination DQB1*0201-0301, whereas the risk was reduced for persons
with the allele pair DQB1*501 or the combination DQA1*0101-DQB1*0501
(12). Other researchers, however, have not been able to confirm that special HLA
class II alleles are relevant in this context (114) and no definite conclusions can
yet be drawn regarding a relationship between HLA type and risk of isocyanate
asthma.
In a retrospective study (17-year follow-up) of 300 exposed workers, a
correlation was found between hypersensitivity to TDI and exposure to high
concentrations of TDI (above 50 ppb, usually a 4:1 mixture of 2,4-TDI and 2,6-
TDI ) (108). The exposure was brought down below 20 ppb, and no new cases of
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TDI hypersensitivity were subsequently seen in a 3-year retrospective follow-up
of workers who worked with TDI daily (108). In another study, IgE antibodies
specific to isocyanates – TDI (unspecified isomer), MDI, HDI – were found in 20
of 94 exposed workers. There was no significant correlation between specific and
total IgE (92). This study includes no analysis of a relationship between symp-
toms and the presence of IgE antibodies. In various other studies, 10 to 30% of
those with isocyanate asthma have been found to have circulating IgE antibodies
specific to albumin-bound isocyanate and/or positive reactions to isocyanates in
prick tests. (21, 25, 58, 64, 143, 151). Despite the fact that the isocyanates are
quite dissimilar in chemical structure, cross-reactions have often been observed
both in vitro (IgE, IgG) and in tests of specific bronchial reactivity (5, 25, 132).
This is believed to be due to the high reactivity of isocyanates and their rapid
formation of complexes with more high-molecular substances, with resulting
sensitization to these new complexes rather than to the isocyanate itself (39). The
correlation between the presence of isocyanate-specific IgE antibodies in blood
and positive reactions to specific bronchial provocation (25) or respiratory symp-
toms (9) is weak, which may indicate that isocyanate-specific IgE antibodies have
only a minor role in isocyanate asthma. In most persons who have isocyanate
asthma it is impossible to find circulating IgE antibodies specific to isocyanate.
In car painters exposed to vapors and aerosols containing HDI (prepolymers
and monomer), titers of IgG specific to HDI prepolymers (but not the monomer)
were significantly higher than in unexposed controls (147). No HDI-specific IgE
antibodies were found in this study.
For many people, the asthma persists despite breaking off the exposure, with
both symptoms and elevated bronchial reactivity to direct stimuli (82, 101). It is
important to diagnose isocyanate asthma early and stop the exposure of persons
who develop it, since early intervention will alleviate the asthma symptoms and
may eliminate the asthma completely (107).
Alveolitis
There are a few reported cases of alveolitis caused by exposure to airborne TDI,
MDI and HDI. This alveolitis is characterized by restrictive reduction in lung
function, interstitial fibrosis, increase of CD8-positive cells in bronchoalveolar
lavage fluid (CD4/CD8 < 1.0) and IgG antibodies specific to albumin-bound
isocyanate (7, 139, 150, 153). In a total of 1,780 isocyanate-exposed workers,
Baur (7) identified 14 cases of dyspnea and fever associated with exposure to
isocyanates. These persons had signs of alveolitis on lung x-rays and/or restrictive
reduction in lung function and/or reduced diffusion capacity and/or IgG anti-
bodies against albumin-bound TDI, MDI or HDI in serum. Bronchoalveolar
lavage and biopsies from the respiratory tract showed inflammatory changes, but
no isocyanate-specific IgE antibodies were found in serum. The average exposure
time was 6 years (0.5-20 years) but cumulative exposures were neither calculated
nor estimated. Baur (7) found the occurrence of alveolitis to be about 1%,
whereas Vandenplas et al. (141) found a prevalence of 4.7% among workers
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occupationally exposed to resins containing MDI or MDI prepolymers. In both
these studies it was remarked that exposure to MDI was more commonly
associated with isocyanate-induced alveolitis than exposure to TDI or HDI. Most
of the alveolitis cases in the Vandenplas study (141) had symptoms so severe that
they had been forced to quit their jobs soon after the symptoms appeared, leading
the authors to postulate that the ‘healthy worker’ effect for isocyanate-induced
alveolitis may be quite large, and that alveolitis caused by isocyanate exposure is
probably more common than these studies indicate. Isocyanate-induced alveolitis
seems to affect non-smokers more than smokers (7).
Other effects on lung function
Long-term exposure to TDI in concentrations below 20 ppb usually causes no
acute symptoms, but it has been argued that it may lead to reduced lung function
(105, 144, 145). A cross-sectional study of workers exposed to MDI (usually
below 20 ppb; a few measurements showing concentrations up to 87 ppb)
revealed that their lung function was lower than that of an unexposed control
group (106). Workers (n = 65) occupationally exposed to air concentrations of
HDI too low to cause symptoms (below the detection limit in 92% of measure-
ments), as well as various organic solvents, showed a small but statistically
significant decline of lung function (FEV1 , FVC) in comparisons with unexposed
controls (n = 68) and workers occupationally exposed to organic solvents alone
(n = 40). This 2.5-year prospective study, however, does not include a group
exposed to HDI alone (2).
The above findings are contradicted by the results of several other studies. In a
9-year study of asymptomatic workers exposed to TDI, their decline in lung
function was no different from that in an unexposed control group (1). TDI-
exposed workers with symptoms, however, showed a more rapid decline in lung
function than the unexposed controls (1). A study by Butcher et al. (20) revealed
no effect on lung function after 2 years of exposure to TDI in the concentration
range 3-54 ppb (average values for 8-hour samples). In a study by Musk et al.
(95), 107 workers in a factory producing polyurethane foam were followed for
5 years. During this period a total of 2,573 monitoring measurements (20 to 60
minutes) of TDI and MDI were made in the breathing zone of the workers. The
average TDI concentration was 1.2 ppb, and 90% of the measurements were
below 5 ppb. The average MDI concentration was 0.6 ppb, with 90% of measure-
ments below 2.2 ppb. No information on exposure peaks is given. Changes in
lung function during the 5 years of the study were the same for exposed indi-
viduals as for controls. No increase in respiratory symptoms and no decline in
lung function were found in the exposed group (95). In a 4-year follow-up of
TDI-exposed workers, lung function changes in 57 exposed workers were the
same as those in 24 workers in a control group. When the exposed workers were
divided into three exposure groups, however, it was found that the 15 workers in
the high-exposure group (TWA 8.2 ppb, with individual top exposures briefly
exceeding 30 ppb) had a more rapid decline in lung function (measured as
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average mid-expiratory flow, FEV1/FVC, and end-expiratory flow) during the
period than the 14 workers in the medium-exposure group (average TDI exposure
1.7 ppb, individual top exposures 3-14 ppb), the 28 workers in the low-exposure
group (average 0.1 ppb, top exposures below 1 ppb), and the control group (100).
In a study by Hathaway et al., no effect on lung function was found in 43
workers after 6 years of occupational exposure to HDI, HDI biuret and HDI
trimer (HDI adducts), when they were compared with 42 controls. HDI concentra-
tions in this study were about 0.5 ppb (2 hours of exposure), and the calculated
12-hour TWA was 0.1 ppb. Daily top exposures averaged 2.9 ppb (44).
Tornling et al. found no difference in lung function changes in a 6-year follow-
up study of non-smoking car painters exposed to HDI and HDI biurettrimer when
they were compared with non-smoking controls who were repair shop metal-
workers and mechanics (138). Exposed smokers, however, had a greater annual
loss of lung function (FVC, VC, FEV1) than smokers in the control group. The
meaning of this is difficult to interpret, since total tobacco exposure is not taken
into account – the only information is whether the subject was a smoker, ex-
smoker or non-smoker. Average exposure in this study was 0.2 ppb, but concen-
trations exceeding 286 ppb were not rare. A significant correlation was found
between decline in FEV over time and the number of occasions with high peak
exposure. This may possibly indicate that, for smokers, decline of lung function
resulting from HDI exposure depends more on brief episodes of high exposure
than on the average long-term exposure. The number of non-smokers in this study
was too small to support any general conclusions drawn from observed effects in
this group. Further, there may have been some exposure of the controls
(especially the metalworkers).
Pham et al. examined 318 workers: 83 not exposed to isocyanates, 117 in-
directly exposed and 118 directly exposed to MDI (106). The concentration of
airborne MDI was on most occasions below 20 ppb, but there were a few
exposure peaks up to 87 ppb. The exposed groups had a slight restrictive
reduction in ventilation capacity when compared with unexposed controls.
Effects on skin
In several case reports of isocyanate-exposed workers with allergic contact
eczema on hands, arms and face, contact allergy (delayed dermal hypersensitivity)
to MDI, TDI and/or HDI has been diagnosed by patch tests (17, 23, 33). Of 15
workers exposed to TDI in the range 70-170 ppb, 5 had a positive patch test for
TDI and 3 had contact eczema caused by TDI (48). Rothe described 12 cases of
contact allergy and allergic contact eczema caused by occupational exposure to
MDI (118). In some cases patients have positive test reactions to several iso-
cyanates, and occasionally to methylene dianiline (MDA) as well – often despite
the fact that they had not previously been exposed to the particular substance that
induced the reaction (33, 68). This has been interpreted as evidence of cross-
reactivity. The patients had been sensitized in jobs such as mold sprayer, car
painter, spray painter and medical technician. Several of them had become
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sensitized because of inadequate protection against skin exposure (work with
worn-out gloves or no gloves, for example), although working conditions were
otherwise good (33, 68). In several cases sensitization occurred after a few weeks
or months of exposure at work (33). In some reported cases the patient had MDI-
or HDI-induced asthma in addition to the contact eczema (33).
Teratogenicity, mutagenicity, carcinogenicity
Animal data, in vitro studies
TDI (2,4-TDI:2,6-TDI, 4:1) and MDI, but not HDI, were mutagenic in Salmonella
typhimurium strains TA1538, TA98 and TA100 with metabolic activation (3).
Changes in DNA conformation were observed in DNA from calf thymus after in
vitro exposure to TDI (2,4-TDI:2,6-TDI, 4:1), but no such effect was obtained
with exposure to MDI or HDI (104). Diisocyanates and their metabolites
(including diamines) form adducts with DNA (142). In vitro incubation with TDI
(2,4-TDI:2,6-TDI, 4:1) caused double strand breaks in leukocytes (88), although
in vitro exposure to pure TDI caused no DNA damage. It was concluded that the
damage is caused by metabolites. On contact with water isocyanates form
aromatic amines, many of which are carcinogenic. TDI (2,4-TDI:2,6-TDI, 4:1)
and a mixture of 45% MDI, 25% 4,4´-methylenediphenyl triisocyanate and 30%
unspecified agent caused chromosome aberrations in human lymphocytes after
24 hours of incubation, without metabolic activation (75).
TDI (86% 2,4-TDI, 14% 2,6-TDI) given orally to mice 5 days/week for
105 weeks (120 or 240 mg/kg/day to males, 60 or 120 mg/kg/day to females)
increased the occurrence (significant dose-response trend) of hemangiomas,
hemangiosarcomas and hepatic adenomas in the females, but not in the males
(49). Oral doses of the same substance given to rats 5 days/week for 106 weeks
(30 or 60 mg/kg/day to males, 60 or 120 mg/kg/day to females) led to significant
increases in the occurrence of subcutaneous fibromas and fibrosarcomas in the
males. The males in the high-dose group also had significantly more pancreatic
adenomas than controls (p = 0.034) (49).
Long-term inhalation exposure to 50 or 150 ppb TDI (2,4-TDI:2,6-TDI, 4:1)
6 hours/day did not increase the occurrence of tumors in either mice (104 weeks
of exposure) or rats (108-110 weeks of exposure) (49).
In a long-term toxicity and carcinogenicity study with Wistar rats, inhalation of
19, 96 or 576 ppb MDI (a mixture of polymers with 44.8-50.2% MDI monomer),
6 hours/day, 5 days/week for 2 years, resulted in lung adenomas in 10% of the
males and 3% of the females in the highest exposure group. One of 60 males in
the high-exposure group also had a lung adenocarcinoma. No lung tumors were
found in controls. In this study, two years of exposure to 576 ppb MDI was
associated with an elevated occurrence of lung tumors, whereas concentrations of
96 ppb or less did not increase the frequency of tumors (112).
2,4-TDA given to mice in feed (100 or 200 mg/kg feed) for 101 weeks
increased the occurrence of hepatocellular carcinomas and lymphomas in the
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females (49). 2,4-TDA given to rats in feed (0.1%) for 36 weeks resulted in liver
carcinomas (55). Rats were given (ad libitum) 2,4-TDA in diet, 125 or 250 mg/kg
feed for 40 weeks followed by 50 or 100 mg/kg feed for 63 weeks. An elevated
occurrence of hepatocellular cancers was seen in both sexes (49). No such effects
were seen with oral administration of 2,6-diaminotoluene. 2,6-TDA in feed given
to mice (50 or 100 mg/kg feed) and rats (250 or 500 mg/kg feed) for 103 weeks
did not increase the frequency of tumors (49).
MDA (4,4´-methylenedianiline ) was tested for carcinogenicity in an NTP
study (146). There was a dose-dependent increase of hepatocellular nodules in
exposed rats. Mice developed hepatocellular cancer. Thyroid adenomas and
carcinomas were seen in the highest dose groups in both species. Smaller or
poorly documented studies also indicate a carcinogenic effect. According to the
IARC, there is ‘sufficient evidence’ that MDA is carcinogenic to experimental
animals (50).
According to the IARC, there is ‘sufficient evidence’ that TDI is carcinogenic
to experimental animals (51), and ‘limited evidence’ that MDI is carcinogenic to
experimental animals (52).
Wistar rats were exposed to MDI 6 hours/day on days 6 to 15 of gestation.
A slight increase in the occurrence of asymmetrical sternums was observed in
fetuses at 864 ppb, but not at 288 ppb, and no other anomalies were noted in
fetuses (19). Food intake by the mothers dropped during the exposures, but no
indications of toxicity were observed and their weight development was no
different from that of controls (19).
Human data
Inhalation of a mixture of MDI (60%), various triisocyanates (30%) and
undefined isocyanates (10%) in concentrations of 5 to 20 ppb increased the
occurrence of double strand breaks in the leukocytes of a 51-year-old worker
occupationally exposed to MDI and MDI oligomers (87). Analyses were made
both before and two hours after an exposure, after the subject had been away from
work for 5 days. As a further control, the blood of a healthy unexposed person
was also examined (87).
Epidemiological studies have revealed no increase in cancer risk for people
exposed to isocyanates. Hagmar et al. made a study of cancer incidence among
4,145 employees who were occupationally exposed to TDI (unspecified isomer)
and MDI at nine polyurethane production facilities. No increase in cancer
incidence could be related to the exposure (42). No increase in the occurrence of
malignant tumors was found in a case-referent study of 7,023 employees at these
workplaces (an expansion of the group covered in Reference 42). In this study
exposure levels were 3.6-414 ppb for TDI and less than 1 ppb for MDI, and
exposures ranged from a few days to more than 10 years (41). Sorahan et al., in a
cohort study of 8,288 workers at 11 polyurethane production facilities in the U.K.,
found no increase in occurrence of malignant tumors (127). In this study the
exposure time was at least 6 months and the exposures were estimated from
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historic data on the jobs done and the associated exposure level. A slight elevation
in the occurrence of pancreatic and lung cancers could be observed among the
women, and was interpreted by the authors as an effect of smoking, possibly in
combination with the occupational exposure (127). No increase in the incidence
of malignant tumors was seen in a cohort study of 4,611 employees at four
different polyurethane production plants in the U.S.A. In this study, estimated
exposure to TDI was below 5.5 ppb during the later part of the observation period
but had previously been higher. The studied cohort had a low average age, and
average duration of employment was only 2.4 years – circumstances which, in the
expressed opinion of the authors, make the results of the study inconclusive (121).
In its updated summary evaluations of carcinogenic risks to humans, the IARC
has placed TDI in Group 2B: ‘possibly carcinogenic to humans,’ and MDI in
Group 3: ‘not classifiable with regard to carcinogenicity to humans’ (51, 52). For
TDI, MDI and HDI, no studies were found of toxic effects on human reproduction
or embryotoxic effects on humans (51, 52)
Dose-response / dose-effect relationships
More pronounced bronchial reactivity to acetylcholine was noted in guinea pigs
after repeated exposure (4 x 1 hour) to TDI in concentrations of 10 or 30 ppb, but
not 5 ppb. Mice exposed by inhalation to 23 ppb 2,4-TDI for 3 hours had a slower
respiratory rate, and the effect was enhanced when exposure was repeated the
following day.
In the studies in which irritation of eyes and respiratory passages was ex-
amined, persons hypersensitive to isocyanates could not be differentiated from
those with normal sensitivity. It was also impossible to differentiate the effects of
irritation, often accompanied by a cough, from the asthma symptoms of those who
had isocyanate asthma.
Asthma-like symptoms (periods of dyspnea and wheezing) were observed in
a rather poorly controlled study in which it was concluded that 2.5 years of
occupational exposure to 0.3-3 ppb TDI increased the risk of developing such
symptoms. This study is flawed by inadequate data presentation and data analysis.
In another study with higher exposures, it was found that long-term exposure to
TDI concentrations in the range 1-25 ppb (median 5 ppb) may lead to asthma
symptoms in previously healthy persons. Persons hypersensitive to isocyanates
may develop asthma symptoms on provocation with a TDI concentration
estimated at 1 ppb.
Too little is known of the relationship between exposure levels and the
development of alveolitis. Six years of occupational exposure to HDI (TWA
0.5 ppb, daily top exposures on average 2.9 ppb) had no effect on lung function
changes, which were the same in exposed workers and controls.
Several studies were excluded from this description of dose-response relation-
ships because they contain exposure measurements made with methods that do
not meet present standards.
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Conclusion
The critical effect of exposure to diisocyanates is development of asthma.
Isocyanate asthma has been observed in persons occupationally exposed to TDI at
workplaces where air concentrations ranged from 1 to 25 ppb (median 5 ppb). In
one study of substandard quality, the development of asthma-like symptoms such
as dyspnea and wheezing was correlated to exposure levels of 0.3 to 3 ppb TDI.
Asthma symptoms have been observed in individuals hypersensitive to iso-
cyanates in conjunction with TDI levels of 5 ppb and estimated TDI levels of
1 ppb.
TDI, MDI and HDI have been shown to be sensitizing to skin.
TDI and a mixture of MDI and its polymers have been shown to induce cancer
in experimental animals. Both substances are considered genotoxic. For HDI,
there are no data on cancer or genotoxicity.
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Acrylamide April 17, 1991 1992:6 (XII)
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Acrylonitrile April 28, 1987 1987:39 (VIII)
Aliphatic amines August 25, 1982 1983:36 (IV)
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Cycloalkanes, C5-C15 April 25, 1984 1984:44 (V)
Cyclohexanone March 10, 1982 1982:24 (III)
revised February 24 1999 1999:26 (XX)
Cyclohexanone peroxide February 13, 1985 1985:32 (VI)
Cyclohexylamine February 7, 1990 1991:8 (XI)
Desflurane May 27, 1998 1998:25 (XIX)
Diacetone alcohol December 14, 1988 1989:32 (X)
Dichlorobenzenes February 11, 1998 1998:25 (XIX)
1,2-Dibromo-3-chloropropane May 30, 1979 1981:21 (I)
Dichlorodifluoromethane June 2, 1982 1982:24 (III)
1,2-Dichloroethane February 29, 1980 1981:21 (I)
Dichloromethane February 29, 1980 1981:21 (I)
Dicumyl peroxide February 13, 1985 1985:32 (VI)
Dicyclopentadiene March 23, 1994 1994:30 (XV)
Diethanolamine September 4, 1991 1992:47 (XIII)
Diethylamine August 25, 1982 1983:36 (IV)
2-Diethylaminoethanol January 25, 1995 1995:19 (XVI)
Diethylene glycol September 16, 1992 1993:37 (XIV)
Diethyleneglycol ethylether + acetate December 11, 1996 1997:25 (XVIII)
Diethyleneglycol methylether + acetate March 13, 1996 1996:25 (XVII)
Diethyleneglycol monobutylether January 25, 1995 1995:19 (XVI)
Diethylenetriamine August 25, 1982 1983:36 (IV)
revised January 25, 1995 1995:19 (XVI)
Diisocyanates April 8, 1981 1982:9 (II)
revised April 27, 1988 1988:32 (IX)
Diisopropylamine February 7, 1990 1991:8 (XI)
N,N-Dimethylacetamide March 23, 1994 1994:30 (XV)
Dimethyl adipate December 9, 1998 1999:26 (XX)
Dimethylamine December 10, 1997 1998:25 (XIX)
N,N-Dimethylaniline December 12, 1989 1991:8 (XI)
Dimethyldisulfide September 9, 1986 1987:39 (VIII)
Dimethylether September 14, 1994 1995:19 (XVI)
92
Dimethylethylamine June 12, 1991 1992:6 (XII)
Dimethylformamide March 23, 1983 1983:36 (IV)
Dimethyl glutarate December 9, 1998 1999:26 (XX)
Dimethylhydrazine January 27, 1993 1993:37 (XIV)
Dimethyl succinate December 9, 1998 1999:26 (XX)
Dimethylsulfide September 9, 1986 1987:39 (VIII)
Dimethylsulfoxide, DMSO December 11, 1991 1992:47 (XIII)
Dioxane August 25, 1982 1983:36 (IV)
revised March 4, 1992 1992:47 (XIII)
Diphenylamine January 25, 1995 1995:19 (XVI)
4,4'-Diphenylmethanediisocyanate (MDI) April 8, 1981 1982:9 (II)
reviderat May 30 2001 2001:20 (XXII)
Dipropylene glycol May 26, 1993 1993:37 (XIV)
Dipropyleneglycol monomethylether December 12, 1990 1992:6 (XII)
Disulfiram October 31, 1989 1991:8 (XI)
Enzymes, industrial June 5, 1996 1996:25 (XVII)
Ethanol May 30, 1990 1991:8 (XI)
Ethanolamine September 4, 1991 1992:47 (XIII)
Ethylacetate March 28, 1990 1991:8 (XI)
Ethylamine August 25, 1982 1983:36 (IV)
Ethylamylketone September 5, 1990 1992:6 (XII)
Ethylbenzene December 16, 1986 1987:39 (VIII)
Ethylchloride December 11, 1991 1992:47 (XIII)
Ethylene December 11, 1996 1997:25 (XVIII)
Ethylene chloride February 29, 1980 1981:21 (I)
Ethylene diamine August 25, 1982 1983:36 (IV)
Ethylene glycol October 21, 1981 1982:24 (III)
Ethylene glycol methylether + acetate June 2, 1999 1999:26 (XX)
Ethyleneglycol monoisopropylether November 16, 1994 1995:19 (XVI)
Ethyleneglycol monopropylether + acetate September 15, 1993 1994:30 (XV)
Ethylene oxide December 9, 1981 1982:24 (III)
Ethylenethiourea September 27, 2000 2001:20 (XXII)
Ethylether January 27, 1993 1993:37 (XIV)
Ethylglycol October 6, 1982 1983:36 (IV)
Ferbam September 12, 1989 1991:8 (XI)
Ferric dimethyldithiocarbamate September 12, 1989 1991:8 (XI)
Flour dust December 10, 1997 1998:25 (XIX)
Formaldehyde June 30, 1979 1981:21 (I)
revised August 25, 1982 1983:36 (IV)
Formamide December 12, 1989 1991:8 (XI)
Formic acid June 15, 1988 1988:32 (IX)
Furfural April 25, 1984 1984:44 (V)
Furfuryl alcohol February 13, 1985 1985:32 (VI)
Gallium + Gallium compounds January 25, 1995 1995:19 (XVI)
Glutaraldehyde September 30 1998 1999:26 (XX)
Glycol ethers October 6, 1982 1983:36 (IV)
Glyoxal September 13, 1996 1996:25 (XVII)
Grain dust December 14, 1988 1989:32 (X)
Graphite December 10, 1997 1998:25 (XIX)
Halothane April 25, 1985 1985:32 (VI)
2-Heptanone September 5, 1990 1992:6 (XII)
3-Heptanone September 5, 1990 1992:6 (XII)
Hexachloroethane September 15, 1993 1994:30 (XV)
Hexamethylenediisocyanate (HDI) April 8, 1981 1982:9 (II)
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revised May 30, 2001 2001:20 (XXII)
Hexamethylenetetramine August 25, 1982 1983:36 (IV)
n-Hexane January 27, 1982 1982:24 (III)
2-Hexanone September 5, 1990 1992:6 (XII)
Hexyleneglycol November 17, 1993 1994:30 (XV)
Hydrazine May 13, 1992 1992:47 (XIII)
Hydrogen bromide February 11, 1998 1998:25 (XIX)
Hydrogen cyanide February 7 2001 2001:20 (XXII)
Hydrogen fluoride April 25, 1984 1984:44 (V)
Hydrogen peroxide April 4, 1989 1989:32 (X)
Hydrogen sulfide May 4, 1983 1983:36 (IV)
Hydroquinone October 21, 1989 1991:8 (XI)
Indium March 23, 1994 1994:30 (XV)
Industrial enzymes June 5, 1996 1996:25 (XVII)
Isophorone February 20, 1991 1992:6 (XII)
Isopropanol December 9, 1981 1982:24 (III)
Isopropylamine February 7, 1990 1991:8 (XI)
Isopropylbenzene June 2, 1982 1982:24 (III)
Lactates March 29, 1995 1995:19 (XVI)
Lactate esters June 2, 1999 1999:26 (XX)
Lead, inorganic February 29, 1980 1981:21 (I)
revised September 5, 1990 1992:6 (XII)
Lithium boron nitride January 27, 1993 1993:37 (XIV)
Lithium nitride January 27, 1993 1993:37 (XIV)
Maleic anhydride September 12, 1989 1991:8 (XI)
Manganese February 15, 1983 1983:36 (IV)
revised April 17, 1991 1992:6 (XII)
revised June 4, 1997 1997:25 (XVIII)
Man made mineral fibers March 4, 1981 1982:9 (II)
revised December 1, 1987 1988:32 (IX)
Mercury, inorganic April 25, 1984 1984:44 (V)
Mesityl oxide May 4, 1983 1983:36 (IV)
Metal stearates, some September 15, 1993 1994:30 (XV)
Methacrylates September 12, 1984 1985:32 (VI)
Methanol April 25, 1985 1985:32 (VI)
Methyl acetate March 28 1990 1991:8 (XI)
Methylamine August 25, 1982 1983:36 (IV)
Methylamyl alcohol March 17, 1993 1993:37 (XIV)
Methyl bromide April 27, 1988 1988:32 (IX)
Methyl chloride March 4, 1992 1992:47 (XIII)
Methyl chloroform March 4, 1981 1982:9 (II)
Methylene chloride February 29, 1980 1981:21 (I)
4,4'-Methylene dianiline June 16, 1987 1987:39 (VIII)
Methyl ethyl ketone February 13, 1985 1985:32 (VI)
Methyl ethyl ketone peroxide February 13, 1985 1985:32 (VI)
Methyl formate December 12, 1989 1991:8 (XI)
Methyl glycol October 6, 1982 1983:36 (IV)
Methyl iodide June 30, 1979 1981:21 (I)
Methylisoamylamine September 5, 1990 1992:6 (XII)
Methyl mercaptane September 9, 1986 1987:39 (VIII)
Methyl methacrylate March 17, 1993 1993:37 (XIV)
Methyl pyrrolidone June 16, 1987 1987:39 (VIII)
α-Methylstyrene November 1 2000 2001:20 (XXII)
Methyl-t-butyl ether November 26, 1987 1988:32 (IX)
revised September 30, 1998 1999:26 (XX)
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Mixed solvents, neurotoxicity April 25, 1985 1985:32 (VI)
Molybdenum October 27, 1982 1983:36 (IV)
Monochloroacetic acid February 20, 1991 1992:6 (XII)
Monochlorobenzene September 16,1993 1993:37 (XIV)
Monomethylhydrazine March 4, 1992 1992:47 (XIII)
Mononitrotoluene February 20, 1991 1992:6 (XII)
Monoterpenes February 17, 1987 1987:39 (VIII)
Morpholine December 8, 1982 1983:36 (IV)
revised June 5, 1996 1996:25 (XVII)
Naphthalene May 27, 1998 1998:25 (XIX)
Natural crystallinic fibers (except asbestos) June 12, 1991 1992:6 (XII)
Nickel April 21, 1982 1982:24 (III)
Nitroethane April 4, 1989 1989:32 (X)
Nitrogen oxides December 11, 1985 1986:35 (VII)
Nitroglycerin February 13, 1985 1985:32 (VI)
Nitroglycol February 13, 1985 1985:32 (VI)
Nitromethane January 6, 1989 1989:32 (X)
Nitropropane October 28, 1986 1987:39 (VIII)
2-Nitropropane March 29, 1995 1995:19 (XVI)
Nitroso compounds December 12, 1990 1992:6 (XII)
Nitrosomorpholine December 8, 1982 1983:36 (IV)
Nitrotoluene February 20, 1991 1992:6 (XII)
Nitrous oxide December 9, 1981 1982:24 (III)
Oil mist April 8, 1981 1982:9 (II)
Organic acid anhydrides, some September 12, 1989 1991:8 (XI)
Oxalic acid February 24, 1988 1988:32 (IX)
Ozone April 28, 1987 1987:39 (VIII)
Paper dust February 7, 1990 1991:8 (XI)
Pentaerythritol November 16, 1994 1995:19 (XVI)
1,1,1,2,2-Pentafluoroethane February 24, 1999 1999:26 (XX)
Pentyl acetate June 14, 2000 2000:22 (XXI)
Peroxides, organic February 13, 1985 1985:32 (VI)
Phenol February 13, 1985 1985:32 (VI)
Phosphorous chlorides September 30, 1998 1999:26 (XX)
Phosphorous oxides February 11, 1998 1998:25 (XIX)
Phthalates December 8, 1982 1983:36 (IV)
Phthalic anhydride September 12, 1989 1991:8 (XI)
Piperazine September 12, 1984 1985:32 (VI)
Plastic dusts December 16, 1986 1987:39 (VIII)
Platinum June 4, 1997 1997:25 (XVIII)
Polyaromatic hydrocarbons February 15, 1984 1984:44 (V)
Polyisocyanates April 27, 1988 1988:32 (IX)
Potassium aluminium fluoride June 4, 1997 1997:25 (XVIII)
Potassium cyanide February 7 2001 2001:20 (XXII)
Potassium dichromate May 24, 2000 2000:22 (XXI)
Potassium hydroxide Marsh 15, 2000 2000:22 (XXI)
2-Propanol December 9, 1981 1982:24 (III)
Propene September 13, 1996 1996:25 (XVII)
Propionic acid November 26, 1987 1988:32 (IX)
Propylacetate September 14, 1994 1995:19 (XVI)
Propylene glycol June 6, 1984 1984:44 (V)
Propylene glycol-1,2-dinitrate May 4, 1983 1983:36 (IV)
Propylene glycol monomethylether October 28, 1986 1987:39 (VIII)
Propylene oxide June 11, 1986 1986:35 (VII)
Pyridine May 13, 1992 1992:47 (XIII)
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Quartz March 13, 1996 1996:25 (XVII)
Resorcinol September 4, 1991 1992:47 (XIII)
Selenium December 11, 1985 1986:35 (VII)
revised February 22, 1993 1993:37 (XIV)
Sevoflurane May 27, 1998 1998:25 (XIX)
Silica March 13, 1996 1996:25 (XVII)
Silver October 28, 1986 1987:39 (VIII)
Sodium cyanide February 7 2001 2001:20 (XXII)
Sodium hydroxide August 24, 2000 2000:22 (XXI)
Stearates, metallic, some September 15, 1993 1994:30 (XV)
Stearates, non-metallic, some November 17, 1993 1994:30 (XV)
Strontium January 26, 1994 1994:30 (XV)
Styrene February 29, 1980 1981:21 (I)
revised October 31, 1989 1991:8 (XI)
Sulfur dioxide April 25, 1985 1985:32 (VI)
Sulfur fluorides March 28, 1990 1991:8 (XI)
Synthetic inorganic fibers March 4, 1981 1982:9 (II)
revised December 1, 1987 1988:32 (IX)
Synthetic organic and inorganic fibers May 30, 1990 1991:8 (XI)
Talc dust June 12, 1991 1992:6 (XII)
Terpenes, mono- February 17, 1987 1987:39 (VIII)
Tetrabromoethane May 30, 1990 1991:8 (XI)
Tetrachloroethane June 4, 1997 1997:25 (XVIII)
Tetrachloroethylene February 29, 1980 1981:21 (I)
1,1,1,2-Tetrafluoroethane March 29, 1995 1995:19 (XVI)
Tetrahydrofuran October 31, 1989 1991:8 (XI)
Tetranitromethane April 4, 1989 !989:32 (X)
Thioglycolic acid June 1, 1994 1994:30 (XV)
Thiourea December 1, 1987 1988:32 (IX)
revised June 2, 1999 1999:26 (XX)
Thiram October 31, 1989 1991:8 (XI)
Thiurams, some October 31, 1989 1991:8 (XI)
Titanium dioxide February 21, 1989 1989:32 (X)
Toluene February 29, 1980 1981:21 (I)
Toluene-2,4-diamine November 1, 2000 2001:20 (XXII)
Toluene-2,6-diamine November 1, 2000 2001:20 (XXII)
Toluene-2,4-diisocyanate April 8, 1981 1982:9 (II)
revised May 30, 2001 2001:20 (XXII)
Toluene-2,6-diisocyanate April 8, 1981 1982:9 (II)
revised May 30, 2001 2001:20 (XXII)
1,1,1-Trifluoroethane February 24, 1999 1999:26 (XX)
Trichlorobenzene September 16, 1993 1993:37 (XIV)
1,1,1-Trichloroethane March 4, 1981 1982:9 (II)
Trichloroethylene December 14, 1979 1981:21 (I)
Trichlorofluoromethane June 2, 1982 1982:24 (III)
1,1,2-Trichloro-1,2,2-trifluoroethane June 2, 1982 1982:24 (III)
Triethanolamine August 25, 1982 1983:36 (IV)
Triethylamine December 5, 1984 1985:32 (VI)
Trimellitic anhydride September 12, 1989 1991:8 (XI)
Trimethylolpropane November 16, 1994 1995:19 (XVI)
Trinitrotoluene April 17, 1991 1992:6 (XII)
Vanadium March 15, 1983 1983:36 (IV)
Vinyl acetate June 6, 1989 1989:32 (X)
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Vinyl toluene December 12, 1990 1992:6 (XII)
White spirit December 16, 1986 1987:39 (VIII)
Wood dust June 17, 1981 1982:9 (II)
revised June 25, 2000 2000:22 (XXI)
Xylene February 29, 1980 1981:21 (I)
Zinc April 21, 1982 1982:24 (III)
Zinc chromate May 24, 2000 2000:22 (XXI)
Zinc dimethyl dithiocarbamate September 12, 1989 1991:8 (XI)
Ziram September 12, 1989 1991:8 (XI)
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